0001493152-17-008899.txt : 20170810 0001493152-17-008899.hdr.sgml : 20170810 20170810170037 ACCESSION NUMBER: 0001493152-17-008899 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170810 DATE AS OF CHANGE: 20170810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vitality Biopharma, Inc. CENTRAL INDEX KEY: 0001438943 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 753268988 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53832 FILM NUMBER: 171022144 BUSINESS ADDRESS: STREET 1: 1901 AVENUE OF THE STARS, 2ND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 BUSINESS PHONE: 530-231-7800 MAIL ADDRESS: STREET 1: 1901 AVENUE OF THE STARS, 2ND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90067 FORMER COMPANY: FORMER CONFORMED NAME: Stevia First Corp. DATE OF NAME CHANGE: 20111020 FORMER COMPANY: FORMER CONFORMED NAME: Legend Mining Inc. DATE OF NAME CHANGE: 20080630 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

  [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2017

 

  [  ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission File Number: 000-53832

 

VITALITY BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   75-3268988

(State or other jurisdiction of

incorporation or organization )

 

(I.R.S. Employer

Identification No.)

 

 

1901 Avenue of the Stars, 2nd Floor    
Los Angeles, CA   90067
(Address of principal executive offices)   (Zip Code)

 

(530) 231-7800
Registrant’s telephone number, including area code

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes[X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 Large accelerated filer [  ] Accelerated filer [  ]

Non-accelerated filer [  ]

(Do not check if a smaller reporting company)

Smaller reporting company [X]

 

Emerging growth company [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of August 9, 2017, there were 23,265,180 shares of the registrant’s common stock outstanding.

 

 

 

 
 

 

VITALITY BIOPHARMA, INC.

Quarterly Report on Form 10-Q

For the Quarterly Period Ended

June 30, 2017

 

INDEX

 

PART I - FINANCIAL INFORMATION 3
   
Item 1. Financial Statements (unaudited) 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
Item 3. Quantitative and Qualitative Disclosures About Market Risk 25
Item 4. Controls and Procedures 25
   
PART II - OTHER INFORMATION 27
   
Item 1. Legal Proceedings 27
Item 1A. Risk Factors 27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27
Item 6. Exhibits 28
   
SIGNATURES 29

 

2 
 

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements (unaudited)

 

VITALITY BIOPHARMA, INC.

CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED JUNE 30, 2017 AND 2016

(Unaudited)

 

CONDENSED UNAUDITED BALANCE SHEETS 4
   
CONDENSED UNAUDITED STATEMENTS OF OPERATIONS 5
   
CONDENSED UNAUDITED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIENCY) 6
   
CONDENSED UNAUDITED STATEMENTS OF CASH FLOWS 7
   
NOTES TO THE CONDENSED UNAUDITED FINANCIAL STATEMENTS 8

 

3 
 

 

VITALITY BIOPHARMA, INC.

CONDENSED BALANCE SHEETS

 

   June 30, 2017   March 31, 2017 
   (unaudited)     
Assets        
         
Current Assets        
Cash  $530,602   $1,152,766 
Accounts receivable, net   25,332    19,198 
Prepaid expenses   3,058    3,058 
           
Total Assets  $558,992   $1,175,022 
           
Liabilities and Stockholders’ Equity (Deficiency)          
           
Current Liabilities          
Accounts payable and accrued liabilities  $306,783   $373,696 
Accrued compensation – officers and directors   151,667    151,667 
Accounts payable - related party   22,000    34,500 
Derivative liability   265,403    240,791 
           
Total liabilities   745,853    800,654 
           
Stockholders’ Equity (Deficiency)          
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 22,265,180 and 22,215,180 shares issued and outstanding, respectively   22,264    22,214 
Additional paid-in-capital   18,633,167    18,088,093 
Accumulated deficit   (18,842,292)   (17,735,939)
Total stockholders’ equity (deficiency)   (186,861)   374,368 
Total liabilities and stockholders’ equity (deficiency)  $558,992   $1,175,022 

 

The accompanying notes are an integral part of these condensed financial statements.

 

4 
 

 

VITALITY BIOPHARMA, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

   Three Months Ended June 30, 
   2017   2016 
         
Revenue  $27,043   $46,377 
Cost of goods sold   20,486    25,119 
Gross profit   6,557    21,258 
           
Operating expenses:          
General and administrative   673,789    327,874 
Research and development   407,009    110,315 
Rent - related party   7,500    6,900 
Total operating expenses   1,088,298    445,089 
           
Loss from operations   (1,081,741)   (423,831)
           
Other income (expenses)          
Change in fair value of derivative liability   (24,612)   (14,953)
Interest expense       (621)
Total other expenses, net   (24,612)   (15,574)
Net loss  $(1,106,353)  $(439,405)
           
Net loss per common share          
Basic and diluted  $(0.05)  $(0.04)
Weighted average number of common shares outstanding          
Basic and diluted   22,255,290    10,069,358 

 

The accompanying notes are an integral part of these condensed financial statements.

 

5 
 

 

VITALITY BIOPHARMA, INC.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIENCY)

THREE MONTHS ENDED JUNE 30, 2017 AND 2016

(Unaudited)

 

        Additional       
   Common Stock   Paid-in   Accumulated     
Description  Shares   Amount   -Capital   Deficit   Total 
                     
Balance- March 31, 2017   22,215,180   $22,214   $18,088,093   $(17,735,939)  $374,368 
Fair value of vested restricted common stock             102,584    —     102,584 
Fair value of vested stock options           342,540    —     342,540 
Fair value of common stock issued for services   50,000    50    99,950    —     100,000 
Net loss               (1,106,353)   (1,106,353)
                          
Balance- June 30, 2017 (unaudited)   22,265,180   $22,264   $18,633,167   $(18,842,292)  $(186,861)

 

The accompanying notes are an integral part of these condensed financial statements.

 

6 
 

 

VITALITY BIOPHARMA, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Three Months Ended June 30, 
   2017   2016 
         
Operating activities        
Net loss  $(1,106,353)  $(439,405)
           
Adjustments to reconcile net loss to net cash used in operating activities          

Fair value of vested stock options

   342,540    39,905 
Amortization of common stock issued to employees with vesting terms   102,584    24,000 
Fair value of common stock issued for services   100,000     
Change in fair value of derivative liability   24,612    14,953 
Fair value of vested warrants granted to employees       35,014 
Changes in operating assets and liabilities:          
Accounts receivable   (6,134)   (8,807)
Deposit   —      (558)
Accounts payable and accrued liabilities   (66,913)   (11,984)
Accounts payable - related party   (12,500)   6,900 
Net cash used in operating activities   (622,164)   (339,982)
           
Financing activities          
Proceeds from common stock issuable       100,000 
Proceeds from sale of common stock, net       165,030 
Net cash provided by financing activities       265,030 
           
Net decrease in cash   (622,164)   (74,952)
           
Cash and cash equivalents - beginning of period   1,152,766    95,433 
Cash and cash equivalent - end of period  $530,602   $20,481 
           
Supplemental disclosure of cash flow information:          
Cash paid during the period for:          
Interest  $   $363 
Income taxes  $   $ 
           
Non-cash activities:          
Extinguishment of derivative liability  $   $80,278 

 

The accompanying notes are an integral part of these condensed financial statements.

 

7 
 

 

VITALITY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED JUNE 30, 2017 AND 2016

(Unaudited)

 

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.

 

In 2015, the Company developed a new class of cannabinoids known as cannabosides, which were discovered through application of the Company’s proprietary enzymatic bioprocessing technologies originally developed for stevia sweeteners. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides.

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2017, the Company incurred a net loss of $1,106,353 and used cash in operating activities of $622,164. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2017 we have sufficient funds to operate the business for the next 6 months. In July 2017, the Company issued an aggregate of 666,667 shares of our common stock and warrants to purchase 333,334 of our common stock to certain investors for net proceeds of approximately $995,000. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

 

We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

 

8 
 

 

Basis of Presentation of Unaudited Condensed Financial Information

 

The unaudited condensed financial statements of the Company for the three months ended June 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2017 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 28, 2017. These financial statements should be read in conjunction with that report.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.

 

Financial Assets and Liabilities Measured at Fair Value

 

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:

 

Level 1 Quoted prices in active markets for identical assets or liabilities.
   
Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
   
Level 3 Unobservable inputs based on the Company’s assumptions.

 

The fair value of the derivative liabilities of $265,403 and $240,791 at June 30, 2017 and March 31, 2017, respectively, were valued using Level 2 inputs.

 

The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2017, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

 

9 
 

 

Stock-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.

 

Basic and Diluted Loss Per Share

 

Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

 

   Three months ended 
   June 30, 2017   June 30, 2016 
Options   2,820,489    892,500 
Warrants   372,421    9,702,713 
Total   3,192,910    10,595,213 

 

Research and Development

 

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.

 

10 
 

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has recently issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, and ASU 2017-05, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. The standard can be adopted either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is currently in the process of analyzing the information necessary to determine the impact of adopting this new guidance on its financial position, results of operations, and cash flows. The Company will adopt the provisions of this statement in the quarter beginning April 1, 2018.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.

 

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 in the third quarter of 2017. The adoption of ASU 2017-11 is not expected to have an impact on the Company’s financial statements and related disclosures because the conversion feature of the Company’s warrants have features other than down round provisions that require current accounting treatment and classification.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

11 
 

 

2. DERIVATIVE LIABILITY

 

In May 2015, the Company issued certain warrants which included an anti-dilution provision that allows for the automatic reset of the exercise price of the warrants upon future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants. In addition, the Company determined that the warrants can be settled for cash at the holders’ option in a future fundamental transaction, as defined. As a result of the anti-dilution and fundamental transaction provisions, the Company determined that the conversion feature of the warrants should be separated from the host contract, be recognized as a derivative liability, and re-measured at each reporting period with the change in value reported in the statement of operations.

 

At March 31, 2017, the balance of the derivative liabilities was $240,791. During the three months ended June 30, 2017, the Company recorded an increase in derivative liability of $24,613. At June 30, 2017, the balance of the derivative liabilities was $265,403.

 

At June 30, 2017 and March 31, 2017, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:

 

   June 30, 2017   March 31, 2017 
Conversion feature:          
Risk-free interest rate   1.14-1.55%   0.19%
Expected volatility   127%   125%
Expected life (in years)   1 to 3 years    1 to 3 years 
Expected dividend yield        
           
Fair Value:          
Conversion feature  $265,403   $240,791 

 

The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

 

3. STOCKHOLDERS’ EQUITY (DEFICIENCY)

 

Common stock issued to employees with vesting terms

 

The Company has issued shares of common stock to employees and directors that vest over time. The fair value of these stock awards are based on the market price of the Company’s common stock on the dates granted, and are amortized over vesting terms ranging up to three years.

 

At March 31, 2017, the accumulated vested balance of stock awards was $952,466. During the three months ended June 30, 2017, we recorded expense related to the fair value of stock awards that vested of $102,504. At June 30, 2017, the amount of unvested compensation related to these awards is approximately $307,750, and will be recorded as expense over 1 year.

 

12 
 

 

Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement.

 

The following table summarizes restricted common stock activity:

 

   Number of Shares 
Non-vested shares, April 1, 2017   1,436,170 
Granted    
Vested    
Forfeited    
Non-vested shares, June 30, 2017   1,436,170 

 

Common stock issued for services

 

During the three months ended June 30, 2017, the Company issued a total of 50,000 shares of common stock to one consultant as payment for services and recorded expenses of $100,000 based on the fair value of the Company’s common stock at the issuance dates.

 

4. STOCK OPTIONS

 

A summary of the Company’s stock option activity during the three months ended June 30, 2017 is as follows:

 

   Shares   Weighted
Average
Exercise Price
 
Balance outstanding at March 31, 2017   2,820,489   $1.27 
Granted         
Exercised         
Expired         
Cancelled         
Balance outstanding at June 30, 2017   2,820,489   $1.27 
Balance exercisable at June 30, 2017   1,006,876   $1.50 

 

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:

 

   Number of
Options
   Weighted
Average
Exercise Price
   Weighted
Average Grant-
date Stock Price
 
Options Outstanding, June 30, 2017   1,710,821   $0.50   $0.50 
    153,000   $0.96   $0.96 
    130,000   $1.00   $10.00 
    10,000   $1.50   $1.50 
    647,500   $2.00 – 2.79    $2.00 – 2.79 
    123,334   $3.10 – 3.80    $3.10 – 3.80 
    45,834   $4.00 – 4.70    $4.00 – 4.70 
    2,820,489           
Options Exercisable, June 30, 2017   427,708   $0.50   $0.50 
    37,500   $0.96   $0.96 
    130,000   $1.00   $10.00 
    7,5000   $1.50   $1.50 
    235,000   $2.00 – 2.79    $2.00 – 2.79 
    123,334   $3.10 – 3.80    $3.10 – 3.80 
    45,834   $4.00 – 4.70    $4.00 – 4.70 
    1,006,876           

 

During the three months ended June 30, 2017, we expensed total stock-based compensation related to stock options of $342,540, and the remaining unamortized cost of the outstanding stock-based awards at June 30, 2017 was approximately $740,000. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years. At June 30, 2017, the 2,820,489 outstanding stock options had an intrinsic value of approximately $3,050,000.

 

13 
 

 

5. WARRANTS

 

At June 30, 2017, warrants to purchase common shares were outstanding as follows:

 

   Shares   Weighted
Average Exercise Price
 
Balance at March 31, 2017   372,421   $2.79 
Granted        
Exercised        
Expired       $ 
Balance outstanding and exercisable at June 30, 2017   372,421   $2.79 

 

6. RELATED PARTY OBLIGATIONS

 

On April 23, 2012, the Company entered into a lease agreement with One World Ranches, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Company’s Board of Directors, and his wife, to rent the space being used as the Company’s principal office and laboratory facility. The original term of the lease was from May 1, 2012 to May 1, 2017. In May 2017, the Company extended the lease through May 1, 2020. Our rent payments thereunder were $2,300 per month until May 1, 2017 and increased to $2,600 per month on May 1, 2017. Aggregate payments under the lease for the three months ended June 30, 2017 and 2016 were $7,500 and $6,900, respectively.

 

7. COMMITMENTS

 

On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. The document requests were primarily in connection with this matter. We have complied with all document requests and the Company’s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of December 2017.

 

As of June 30, 2017, we had accrued approximately $44,000 in legal fees related to the SEC examination.

 

14 
 

 

8. SUBSEQUENT EVENTS

 

On July 26, 2017, the Company entered into a Securities Purchase Agreement with the purchasers identified therein providing for the issuance and sale by the Company to the purchasers, of an aggregate of 666,667 shares of the Company’s common stock (collectively, the “Shares”) and Warrants to purchase up to an aggregate of 333,334 shares of the Company’s common stock (the “Warrants”), at a price of $1.50 per share (the “Offering”). The Warrants have an exercise price of $2.00 per share, are exercisable immediately, expire on the three year anniversary of the date of issuance, and may be exercised on a cashless basis. The Offering closed on July 28, 2017. The aggregate proceeds to the Company from the sale of the Shares and Warrants was approximately $995,000.

 

In July 2017, we issued options to purchase 30,000 shares of our common stock to a consultant with a fair value of $50,127 at grant date. These options have an exercise price of $1.79 per share and expire ten years from the date of issuance. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.91%, (ii) discount rate of 2.20 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The fair value of the option grants to the consultants will be recalculated each quarter and will be amortized over 24 months as the options vest based on their fair value at the end of each quarterly reporting period.

 

15 
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

As used in this discussion and analysis and elsewhere in this Quarterly Report, the “Company”, “we”, “us” or “our” refer to Vitality Biopharma, Inc., a Nevada corporation.

 

Cautionary Statement

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Unaudited Condensed Financial Statements and the related notes thereto contained in Part I, Item 1 of this Quarterly Report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed on June 28, 2017, and the related audited financial statements and notes included therein.

 

Certain statements made in this Quarterly Report on Form 10-Q constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These risks and uncertainties include: general economic and financial market conditions; our ability to obtain additional financing as necessary; our ability to continue operating as a going concern; any adverse occurrence with respect to our business or; results of our research and development activities that are less positive than we expect ; our ability to bring our intended products to market; market demand for our intended products; shifts in industry capacity; product development or other initiatives by our competitors; fluctuations in the availability of raw materials and costs associated with growing raw materials for our intended products; poor growing conditions for the stevia plant; other factors beyond our control; and the other risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on June 28, 2017.

 

Although we believe that the expectations and assumptions reflected in the forward-looking statements we make are reasonable, we cannot guarantee future results, levels of activity or performance. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those expressed by any forward-looking statements. As a result, readers should not place undue reliance on any of the forward-looking statements we make in this report. Forward-looking statements speak only as of the date on which they are made. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

 

Company Overview

 

We were incorporated in the State of Nevada on June 29, 2007 under the name Legend Mining Inc. On October 10, 2011, we completed a merger with our wholly-owned subsidiary, Stevia First Corp., whereby we changed our name from “Legend Mining Inc.” to “Stevia First Corp.” Also on October 10, 2011, we effected a seven for one forward stock split of authorized, issued and outstanding common stock. As a result, our authorized capital was increased from 75,000,000 shares of common stock with a par value of $0.001 to 525,000,000 shares of common stock with a par value of $0.001, and issued and outstanding shares of common stock increased from 7,350,000 to 51,450,000. In February 2012, we substantially changed our management team, and added other key personnel. In December 2015, we discovered novel pharmaceutical applications of our glycosylation technology for producing cannabinoid prodrugs and we have recently changed our operational focus towards pharmaceutical development of the cannabinoid prodrugs. On July 15, 2016, the holders of a majority of our outstanding common stock and our Board of Directors approved 1) a name change whereby our name changed from Stevia First Corp. to Vitality Biopharma, Inc., 2) a reverse split of our outstanding common shares whereby each 10 shares of common stock will be exchanged for 1 share of common stock and 3) an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These changes became effective on July 20, 2016.

 

16 
 

 

Plan of Operations

 

Business Overview

 

Vitality Biopharma is unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, such as inflammatory bowel disease and narcotic bowel syndrome, a form of severe opiate-induced bowel dysfunction.

 

Vitality Biopharma has developed a new class of cannabinoid pharmaceuticals known as cannabosides, which were discovered in 2015 through application of the company’s proprietary enzymatic bioprocessing technologies originally developed for stevia sweeteners. Cannabosides are cannabinoid glycoside “prodrugs,” which means that they are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which already has a long history of clinical investigation and use. A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid. Because there already exists independent verification of the active drug’s safety and efficacy, prodrugs may receive marketing approval more quickly than others, and in some cases may receive drug approvals through completion of small clinical studies evaluating bioequivalence or bioavailability. At the same time, a prodrug can have many commercial advantages, including that they can be proprietary and patentable compositions of matter, unlike cannabinoids themselves, or older pharmaceutical formulations where patent protection has already expired.

 

Cannabosides are more stable and soluble than cannabinoids, and upon oral delivery, cannabinoids pass through the digestive tract and release within the large intestine or colon. This enables targeted delivery of cannabinoids for the treatment of gastrointestinal disorders. Cannabosides enable the reduction or elimination of systemic delivery of tetrahydrocannibinol (THC) into the bloodstream and brain, reducing psychoactive side effects, and enabling higher concentrations of compounds to be used for treatment of pain and inflammation. Targeted delivery with limited psychoactivity may be especially useful for treatment of pediatric conditions. Because passage of cannabosides through the digestive tract is likely to occur over several hours or longer, there is a sustained or delayed release of cannabinoids, which may provide patients with long-lasting or overnight relief, a desirable attribute that is unavailable with medical marijuana or with current cannabinoid pharmaceutical formulations.

 

We have produced more than 25 novel cannabosides so far and have patent applications that include composition of matter claims for prodrugs of cannabinoids that have been studied extensively in clinical trials worldwide, including THC, cannabidiol (CBD), cannabidivarin (CBDV), and other phytocannabinoids and endocannabinoids. Upon successful patent prosecution, protection would extend until 2035 and be available in all major markets worldwide. In addition, we have filed composition of matter claims on vanilloid glycoside compounds that target the TRPV receptors, which mediate pain relief, and on the use of TRPV1 agonists for effecting neural repair. We aim to develop and approve our proprietary molecules as pharmaceuticals using a low-risk regulatory strategy that is available for prodrugs, and to amplify the benefits that have been seen in independent clinical trials describing the use of cannabinoids for treatment of neurological and inflammatory conditions.

 

A key part of our strategy will be to take advantage of a more efficient FDA review and approval process that is available for prodrugs, which reduces the need for large and expensive clinical trials. Expedited regulatory processes may be available for our cannabosides because in the U.S. and internationally there have already been many independent preclinical and clinical studies completed using the reference cannabinoid drugs we are studying, and so existing clinical data may be submitted to drug regulatory agencies as supporting evidence of our compounds’ safety and efficacy.

 

We are initially developing our cannabosides drug formulations for treatment of inflammatory bowel disease as well as narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.

 

17 
 

 

For inflammatory bowel disease (IBD), there have been independently-conducted preclinical and clinical studies that have demonstrated the benefit of cannabinoids, and many U.S. states now permit the use of medical marijuana for IBD, including for treatment of Crohn’s disease or ulcerative colitis patients. Independently-run retrospective clinical studies have found that in 56 patients who used cannabinoids with IBD that 83.9% of patients reported improvement in abdominal pain and 76.8% of patients reported improvement in abdominal cramping. In addition, in a prospective trial that was independently-managed and placebo-controlled, it was found that 45% of Crohn’s disease patients achieved remission through only 8 weeks of treatment. Patients reported improvements in sleep and appetite with no significant side effects, and some patients were able to eliminate use of corticosteroids and opiate pain medications. Patients experienced benefits with cannabis treatment despite being non-responders to traditional front-line therapies, such as corticosteroids, immunomodulators, and biologic TNF-alpha inhibitors.

 

In early 2017, we obtained new data about the anti-cancer and anti-microbial properties of cannabinoids, including evidence that cannabinoids provide cytotoxicity against cell lines of colorectal cancer and C.difficile, a drug-resistant microbial infection that colonizes the large intestine. Both colorectal cancer and C.difficile infections are more prevalent in IBD patients than in the general population.

 

Narcotic bowel syndrome (NBS) is a severe form of opiate-induced abdominal pain. In studies, more than half (58%) of opiate users have reported chronic abdominal pain. When opiate-induced abdominal pain is overlooked or misdiagnosed, potentially due to common gastrointestinal side effects like opiate-induced constipation, it may lead to a vicious cycle of dose escalation. While seeking pain relief, increasing the dose of opiate medications could lead both to worsening abdominal pain and to more severe drug addiction. Studies have reported that approximately 6% of opiate users have NBS, and that patients afflicted with this disorder report a quality-of-life that is worse than patients with quadriplegia. Independent preclinical studies have reported that endogenous opioid peptides may play a role within the intestinal tract in the development of inflammation, and that they act in a synergistic manner to cannabinoids for pain relief, meaning that cannabinoids could enable opiate dose reduction without sacrificing pain relief. Independent clinical studies have confirmed this effect, where it was reported that cannabis provides additional pain relief to patients taking stable doses of opiates for chronic pain management,. Independent clinical studies have also found that treatment regimens for narcotic bowel syndrome are ineffective, as 45.8% of patients were shown to return to using narcotics within only three months.

 

We plan to complete preclinical studies necessary to commence clinical trials in 2017, which will focus initially on evaluating the clinical pharmacokinetics and safety of cannabosides, and to then evaluate their utility for treatment of inflammatory bowel disease and narcotic bowel syndrome. We plan to conduct additional preclinical studies also, which will evaluate the utility of cannabosides as a chronic therapy for treatment of additional conditions such as neuropathic pain, irritable bowel syndrome, colorectal cancer, C. difficile infections, muscle spasticity in multiple sclerosis, and opiate-induced bowel dysfunction.

 

Our primary operations are based in Yuba City, California, where we originally developed our proprietary bioprocessing methods. The Company’s research and development facilities include laboratories and a manufacturing suite that will be used for pharmaceutical-grade production of cannabosides for clinical trials. These facilities have been registered with and approved by the DEA as well as the State of California.

 

Product Pipeline

 

Our pipeline includes drug formulations of cannabosides, which are cannabinoid glycoside prodrugs. Prodrugs are medications or compounds metabolized by the body into a pharmacologically active drug. We have patents pending for more than 25 of these novel pharmaceutical compositions including prodrugs of THC, CBD, and CBDV, which are cannabinoids that are either marketed and approved as pharmaceutical products today, or that are currently under investigation in independent clinical trials. Prodrugs can optimize the marketability of a drug because they can be patented and proprietary, and yet still be approved through an abbreviated regulatory pathway.

 

VITA-100 is an oral cannabinoid formulation containing cannabosides that is being developed for acute treatment of inflammatory bowel disease and narcotic bowel syndrome. VITA-210 is an or cannabinoid formulation containing cannabosides being investigated in preclinical studies for chronic administration, and which may be applied towards treatment of neuropathic pain, irritable bowel syndrome, colorectal cancer, C. difficile infections, muscle spasticity in multiple sclerosis, and opioid-induced bowel dysfunction.

 

18 
 

 

We believe that through a process called glycosylation, the solubility and stability of a drug can be significantly improved. Cannabinoid glycoside prodrugs and their use in drug formulations that we are currently developing are designed to enable significant benefits, including:

 

  1. Administration of cannabinoids in a convenient oral formulation;
     
  2. Targeted delivery of compounds to specific tissues or organs, especially targeted delivery of cannabinoids to the colon or large intestine, which can reduce or eliminate the delivery of psychoactive compounds into the bloodstream and brain;
     
  3. Improved solubility, leading to oral formulations that are easy to manufacture and that improve the taste of products through reduction or removal of harsh organic solvents;
     
  4. Improved stability, preventing conversion of CBD to unwanted byproducts including THC in the acidic stomach environment, or other forms of degradation, and therefore enabling higher doses to be administered orally; and
     
  5. Delayed release, enabling long-lasting and overnight relief for patients, rather than having to administer treatment repeatedly throughout the day and requiring additional sleep aids.

 

Drug   Treatment Indications   Status
         
Cannabosides - VITA-100   Inflammatory Bowel Disease, Narcotic Bowel Syndrome, Clostridium Difficile Infections   Phase 1a/1b Trial Expected to Initiate in 2017
         
Cannabosides - VITA-210   Neuropathic Pain, Irritable Bowel Syndrome, Colorectal Cancer, Muscle Spasticity in Multiple Sclerosis & Rare White Matter Disorders, Opiate-Induced Bowel Dysfunction   Phase 1 Trial Expected to Initiate in 2017
         
Additional Cannabosides Formulations   Epilepsy, Schizophrenia, Huntington’s disease, Guillain-Barré   Preclinical

 

We also have licensed intellectual property that seeks to protect methods for treatment of multiple sclerosis and demyelinating disorders using TRPV1 agonists. These compounds may be tested either as standalone agents or in combination with our cannaboside drug formulations in order to establish treatment regimens that provide regenerative effects for patients with serious neurological and inflammatory conditions.

 

Our Operations

 

For each of the pharmaceutical products in our pipeline, the active cannabinoid pharmaceutical agents have either been independently approved by regulatory bodies, or are now in late-stage clinical trials, and there is extensive clinical data already available related to drug safety and effectiveness. Because of this, we will in general benefit from the increased familiarity of clinical investigators and regulators with these compounds, which may enable abbreviated paths towards clinical testing and eventual approval of our pharmaceutical products.

 

19 
 

 

Cannabinoids are known to be effective anti-inflammatory and neuroprotective agents, and as of 2016, U.S. states containing 87% of the U.S. population have enacted medical marijuana laws to permit access to medical cannabis for treatment of a variety of conditions, including at least use of CBD, which is not intoxicating. The approved disease indications include ones directly related to the drug indications we are targeting, as well as many others. The list includes chronic pain, inflammatory bowel disease, epilepsy, wasting disorders, multiple sclerosis and muscle spasticity disorders, glaucoma, cirrhosis, Alzheimer’s disease, nausea, traumatic brain injury, Parkinson’s disease, HIV/AIDS, Huntington’s disease, and more. Cannabinoid pharmaceuticals are increasingly being approved as well, including primarily synthetic and botanical extracts of the two major constituents of Cannabis sativa, which are THC and CBD. Dronabinol is a synthetic THC drug that has been approved for treating nausea and for stimulating appetite. Nabiximols is a blend of two cannabinoids, THC and CBD, which has been approved in more than 20 countries for treatment of muscle spasticity in multiple sclerosis, and also for treatment of cancer pain in certain countries.

 

CBD is not intoxicating, has established antianxiety and antipsychotic effects, and beyond its inclusion in nabiximols, is also being investigated independently by clinical researchers as a stand-alone agent for epilepsy, schizophrenia, inflammatory bowel disease, opiate dependence, and a variety of other neurological and inflammatory conditions. We intend to obtain marketing authorizations in one or more of these disease indications, while focusing initially on inflammatory bowel disease and narcotic bowel syndrome.

 

Short Term Development Targets

 

  Complete preclinical efficacy and toxicology trials to support clinical development of cannabosides
     
  Complete additional preclinical efficacy and pharmacology studies of cannabosides and cannaboside drug formulations that support lead drug indications as well as novel therapeutic applications
     
  Complete the manufacture of cannaboside formulations that will be used in initial clinical studies
     
  Obtain regulatory approval for first-in-man clinical studies to evaluate the pharmacokinetics of cannabosides, and to obtain preliminary data about their efficacy for providing relief of key symptoms that are common to inflammatory bowel disease and narcotic bowel syndrome

 

We believe that our long-term commercial success and profit potential depends in large part on our ability to develop and advance proprietary cannabinoid prodrugs that are strongly differentiated from both medical cannabis and existing cannabinoid drugs, and to do this more quickly, efficiently and effectively than our competitors. Another critical factor that will determine our success is our ability to obtain and enforce patents, maintain protection of trade secrets, and operate our business without infringing the proprietary rights of third parties. As a result, we are dedicated to the continued development and protection of our intellectual property portfolio. See “Intellectual Property” in this report for a further discussion.

 

Additional Operations

 

Our glycosylation technology in the past was applied primarily to production of better tasting varieties of stevia through enzyme bioprocessing, which was developed in concert with additional technologies designed to improve the taste and yield of stevia sweetener derived from the stevia plant. We have an intellectual property portfolio related to stevia, as well as commercial operations related to the manufacture and sale of research products that commenced in 2014. We intend to sustain these operations and technologies in a manner that is cash-flow neutral or better and to commercialize them primarily through new out-licensing arrangements or strategic partnerships.

 

Results of Operations

 

Three Months Ended June 30, 2017 and June 30, 2016

 

Our net loss during the three months ended June 30, 2017 was $1,106,353 compared to a net loss of $439,405 for the three months ended June 30, 2016. During the three months ended June 30, 2017, we generated $27,043 in revenue and $6,557 in gross profit, compared to $46,377 in revenue and $21,258 in gross profit for the 2016 period. Our revenue in each of the periods presented is earned from the sale of research diagnostic testing kits and chemicals. We expect such sales to continue at approximately the rate during the 2017 period.

 

20 
 

 

During the three months ended June 30, 2017, we incurred general and administrative expenses in the aggregate amount of $673,789 compared to $327,874 incurred during the three months ended June 30, 2016 (a decrease of $345,915. General and administrative expenses generally include corporate overhead, salaries and other compensation costs, financial and administrative contracted services, marketing, consulting costs and travel expenses. A significant portion of these costs are related to the development of our organizational capabilities as a biotechnology company, including costs such as legal and advisory fees related to intellectual property development. The majority of the increase in general and administrative costs in the period relates to stock-based compensation costs which increased to $545,124 in the period ending June 30, 2017, as compared to $98,919 in the period ending June 30, 2016.

 

In addition, during the three months ended June 30, 2017, we incurred research and development costs of $407,009, compared to $110,315 during the three months ended June 30, 2016 (an increase of $296,694). This decrease resulted from increased laboratory and consulting expenses during the 2017 period.

 

During the three months ended June 30, 2017, we incurred related party rent and other costs totaling $7,500 compared to $6,900 incurred during the three months ended June 30, 2016.

 

This resulted in a loss from operations of $1,081,741 during the three months ended June 30, 2017 compared to a loss from operations of $423,831 during the three months ended June 30, 2016.

 

During the three months ended June 30, 2017, we recorded total net other income (expense) in the amount of $(24,612), compared to total net other income (expense) recorded during the three months ended June 30, 2016 in the amount of $(15,574). During the three months ended June 30, 2017, we recorded an expense related to the change in fair value of derivatives of $24,612, compared to an expense of $14,953 during the 2016 quarter. This resulted in a net loss of $1,106,353 during the three months ended June 30, 2017 compared to a net loss of $439,405 during the three months ended June 30, 2016.

 

The net loss during the three months ended June 30, 2017 compared to the net loss for the three months ended June 30, 2016 is attributable primarily to the higher stock based compensation and research and development costs in the 2017 period.

 

Liquidity and Capital Resources

 

As of June 30, 2017, we had total current assets of $558,992, which was comprised mainly of cash of $530,602. Our total current liabilities as of June 30, 2017 were $745,853 and consisted of accounts payable and accrued liabilities of $306,783, accrued compensation owed to officers and directors of $151,667 and accounts payable to a related party of $22,000, and derivative liability of $265,403. The derivative liability is a non-cash item related to certain of our outstanding warrants as of June 30, 2017. As a result, on June 30, 2017, we had working capital deficit of $186,861.

 

We have not yet received significant revenues from sales of products or services, and have recurring losses from operations. We have incurred losses since inception resulting in stockholders’ deficit of $186,861 as of June 30, 2017, and further losses are anticipated in the development of our business. These factors raise substantial doubt about our ability to continue as a going concern. Our financial statements included in this report have been prepared on a going concern basis, which assumes that we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. The continuation of our Company as a going concern is dependent upon our Company attaining and maintaining profitable operations and raising additional capital. The financial statements included in this report do not include any adjustments relating to the recovery and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should our Company discontinue operations.

 

21 
 

 

Due to the uncertainty of our ability to meet our current operating expenses and capital expenses as noted above, in their report on our annual financial statements for the year ended March 31, 2017, our independent auditors included an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors. We estimate that we will have sufficient funds to operate the business for the 6 months after June 30, 2017. In July 2017, the Company issued an aggregate of 666,667 shares of our common stock and warrants to purchase 333,334 of our common stock to certain investors for net proceeds of approximately $995,000. We will require additional financing to fund our planned long-term operations. These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

 

We do not have any firm commitments for future capital. Significant additional financing will be required to fund our planned operations in future periods, including research and development activities relating to our principal product candidate, seeking regulatory approval of that or any other product candidate we may choose to develop, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, revenue to fund our business from our operations, and will need to obtain significant funding from external sources. We may seek to raise such funding from a variety of sources. If we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, we may not be able to obtain additional financing from any of these sources on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

 

Sources of Capital

 

On July 26, 2017, the Company entered into a Securities Purchase Agreement with the purchasers identified therein providing for the issuance and sale by the Company to the purchasers, of an aggregate of 666,667 shares of the Company’s common stock (collectively, the “Shares”) and Warrants to purchase up to an aggregate of 333,334 shares of the Company’s common stock (the “Warrants”), at a price of $1.50 per share (the “Offering”). The Warrants have an exercise price of $2.00 per share, are exercisable immediately, expire on the three year anniversary of the date of issuance, and may be exercised on a cashless basis. The Offering closed on July 28, 2017. The aggregate proceeds to the Company from the sale of the Shares and Warrants was approximately $995,000.

 

On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. We have complied with all document requests and the Company’s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of December 2017..

 

22 
 

 

Net Cash Used in Operating Activities

 

We have not generated positive cash flows from operating activities. For the three months ended June 30, 2017, net cash used in operating activities was $622,164 compared to net cash used in operating activities of $339,982 for the three months ended June 30, 2016. This increase was primarily attributable to an increase in research and development costs. Net cash used in operating activities during the three months ended June 30, 2017 consisted primarily of a net loss of $1,106,353, offset by $545,124 related to stock-based compensation and change in fair value of derivative liability of $24,612. Net cash used in operating activities during the three months ended June 30, 2016 consisted primarily of a net loss of $439,405, offset by $98,919 related to stock-based compensation and change in fair value of derivative liability of $14,953.

 

Net Cash Used in Investing Activities

 

During the three months ended June 30, 2017 and June 30, 2016, no net cash was used in or provided by investing activities.

 

Net Cash Provided By Financing Activities

 

During the three months ended June 30, 2017, no net cash was used in or provided by financing activities compared to net cash provided by financing activities of $265,030 for the three months ended June 30, 2016. Net cash provided by financing activities during the three months ended June 30, 2016 and was attributable to the sale of common stock and warrants.

 

Off-Balance Sheet Arrangements

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that would be material to stockholders.

 

Critical Accounting Policies

 

Our financial statements and accompanying notes included in this report have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) applied on a consistent basis. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from the estimates made by management.

 

We believe the following critical accounting policies require us to make significant judgments and estimates in the preparation of our consolidated financial statements included in this report:

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumption by management include, among others, the fair value of shares issued for services, the fair value of options and warrants, and assumptions used in the valuation of our outstanding derivative liabilities.

 

23 
 

 

Stock-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the Financial Accounting Standards Board (FASB”) Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

Derivative Financial Instruments

 

We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, we use a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2017 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

 

Recent Accounting Pronouncements

 

Please refer to Footnote 1 of the accompanying financial statements for management’s discussion of recent accounting pronouncements

 

24 
 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not Applicable.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our principal executive and financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this report. Based on this evaluation, our principal executive and financial officer concluded that as of June 30, 2017, these disclosure controls and procedures were not effective to ensure that the information required to be disclosed by our Company in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (“SEC”), including that such information is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosures .. The conclusion that our disclosure controls and procedures were not effective was due to the presence of material weaknesses in our internal control over financial reporting, as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as previously disclosed in Item 9A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2017. In light of the material weaknesses identified by management, we performed additional analyses and procedures in order to conclude that our condensed financial statements for the interim period ended June 30, 2017 are fairly presented, in all material respects, in accordance with GAAP.

 

Description of Material Weaknesses and Management’s Remediation Initiatives

 

As of the date of this report, our remediation efforts continue related to each of the material weaknesses that we have identified in our internal control over financial reporting and additional time and resources will be required in order to fully address these material weaknesses. We have not been able to complete all actions necessary and test the remediated controls in a manner that would enable us to conclude that such controls are effective. We are committed to implementing the necessary controls to remediate the material weaknesses described below, as and when resources permit. These material weaknesses will not be considered remediated until (1) the new processes are designed, appropriately controlled and implemented for a sufficient period of time and (2) we have sufficient evidence that the new processes and related controls are operating effectively. The following is a list of the material weaknesses identified by management as of June 30, 2017:

 

(1) Insufficient segregation of duties in our finance and accounting functions due to limited personnel. During the three months ended June 30, 2017, we internally performed all aspects of our financial reporting process, including, but not limited to, access to the underlying accounting records and systems, the ability to post and record journal entries and responsibility for the preparation of the financial statements. Due to the fact that these duties were often performed by the same person, there was a lack of review over the financial reporting process that might result in a failure to detect errors in spreadsheets, calculations, or assumptions used to compile the financial statements and related disclosures as filed with the SEC. This could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected.

 

(2) Insufficient corporate governance policies. The Company does not have a majority of independent members on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

 

25 
 

 

Changes in Internal Control over Financial Reporting

 

We are currently considering adding additional independent members to our board of directors and adding accounting personnel to our staff in connection with the ongoing efforts to remediate the material weaknesses described above, but no specific progress has been made on these goals or other remediation efforts during the three months ended June 30, 2017. As a result, there were no changes in our internal control over financial reporting during the three months ended June 30, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations on Internal Control

 

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple errors. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. In addition, projections of any evaluation of effectiveness to future periods are subject to risks that controls that are effective at one date may subsequently become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate.

 

26 
 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party to and our properties are not currently the subject of any material pending legal proceedings the adverse outcome of which, individually or in the aggregate, would be expected to have a material adverse effect on our financial position or results of operations.

 

Item 1A. Risk Factors

 

Please refer to the risks described under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on June 28, 2017.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

27 
 

 

Item 6. Exhibits

 

Exhibit
Number
  Description of Exhibit
     
4.1   Form of Common Stock Purchase Warrant (Incorporated by reference to Exhibit 4.1 to the registrant’s Current Report on Form 8-K filed with the SEC on July 27, 2017.)
     
10.1   Securities Purchase Agreement, dated July 26, 2017 by and among Vitality Biopharma, Inc., and the Purchasers listed on the signature pages thereto (Incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the SEC on July 27, 2017.)
     
10.2   Registration Rights Agreement, dated July 26, 2017, by and among Vitality Biopharma, Inc. and the Purchasers listed on the signature pages thereto (Incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the SEC on July 27, 2017.)
     
10.3  

Lease Renewal Agreement, dated May 1, 2017, by and between the registrant and One World Ranches LLC.*

     
31.1   Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*
     
32.1   Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†
     
101.INS   XBRL Instance Document *
     
101.SCH   XBRL Taxonomy Extension Schema Document *
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase *
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document *
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document *
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document *

 

 

* Filed herewith.

† Furnished herewith.

 

28 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

VITALITY BIOPHARMA, INC.  
     
By: /s/ Robert Brooke  
  Robert Brooke  
  Chief Executive Officer  
  (Principal Executive Officer and Principal Financial and Accounting Officer)  
     
Date: August 10, 2017  

 

29 
 

 

EXHIBIT INDEX

 

Exhibit
Number
  Description of Exhibit
     
4.1   Form of Common Stock Purchase Warrant (Incorporated by reference to Exhibit 4.1 to the registrant’s Current Report on Form 8-K filed with the SEC on July 27, 2017.)
     
10.1   Securities Purchase Agreement, dated July 26, 2017 by and among Vitality Biopharma, Inc., and the Purchasers listed on the signature pages thereto (Incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the SEC on July 27, 2017.)
     
10.2   Registration Rights Agreement, dated July 26, 2017, by and among Vitality Biopharma, Inc. and the Purchasers listed on the signature pages thereto (Incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K filed with the SEC on July 27, 2017.)
     
10.3   Lease Renewal Agreement, dated May 1, 2017, by and between the registrant and One World Ranches LLC.*
     
31.1   Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*
     
32.1   Certification of Chief Executive Officer (Principal Executive Officer and Principal Financial and Accounting Officer) Pursuant to Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002†
     
101.INS   XBRL Instance Document *
     
101.SCH   XBRL Taxonomy Extension Schema Document *
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase *
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document *
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document *
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document *

 

 

* Filed herewith.

† Furnished herewith.

 

30 
 

 

EX-10.3 2 ex10-3.htm

 

Exhibit 10.3 

 

RENEWAL OF LEASE AGREEMENT

 

This Renewal of Lease Agreement (“Renewal”) is entered into and made effective as of May 1, 2017, by and between One World Ranches LLC, a California limited liability company (“Lessor”), and Vitality Biopharma, Inc.

 

WHEREAS, Lessor and Lessee entered into a lease agreement dated April 23, 2012 (the “Lease”);

 

WHEREAS, the Lease will expire on May 1, 2017; and

 

WHEREAS, the Lessor and Lessee wish to extend the term of the Lease.

 

NOW THEREFORE, in consideration of the mutual agreements and promises set forth herein, Lessor and Lessee agree as follows:

 

1. The term of the Lease is extended from May 1, 2017 to May 1, 2020.

 

2. The monthly rent shall be increased to $2,600.00 beginning on May 1, 2017 during the term of the Lease.

 

3. Except as expressly modified herein, all of the terms of the Lease are unchanged and remain in full force and effect.

 

   
 

 

The parties have executed and entered into this Lease on the date and year first above written.

 

  LESSOR:
   
  One World Ranches LLC, a California Limited Liability Company
     
  By: /s/ Diljit Baines
     
    Diljit Bains, Member

 

  LESSEE:
   
  Vitality Biopharma, Inc., a Nevada Corporation
     
  By: /s/ Robert Brooke
     
    Robert Brooke, Chief Executive Officer

 

  2 
 

 

 

EX-31.1 3 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Robert Brooke , certify that:

 

  1. I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2017 of Vitality Biopharma, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 10, 2017

 

Name: /s/ Robert Brooke  
By: Robert Brooke  
Title: Chief Executive Officer  
  (Principal Executive Officer and Principal Financial and Accounting Officer)  

 

 
 

 

 

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

 

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Robert Brooke, the Chief Executive Officer of Vitality Biopharma, Inc. (the “Company”), hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q for the period ended June 30, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company as of the dates and for the periods presented in the financial statements included in such report.

 

/s/ Robert Brooke  
Robert Brooke  
Chief Executive Officer  
(Principal Executive Officer and  
Principal Financial and Accounting Officer)  
   
Date: August 10, 2017  

 

This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 
 

 

 

EX-101.INS 5 vbio-20170630.xml XBRL INSTANCE FILE 0001438943 2017-04-01 2017-06-30 0001438943 2016-03-31 0001438943 2017-03-31 0001438943 us-gaap:WarrantMember 2016-04-01 2016-06-30 0001438943 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001438943 us-gaap:MaximumMember 2016-04-01 2017-03-31 0001438943 us-gaap:MinimumMember 2016-04-01 2017-03-31 0001438943 vbio:LeaseAgreementMember vbio:OneWorldRanchesMember 2012-04-01 2012-04-23 0001438943 us-gaap:RestrictedStockMember 2017-03-31 0001438943 vbio:StockOptionsOneMember 2017-06-30 0001438943 vbio:StockOptionsTwoMember 2017-06-30 0001438943 vbio:StockOptionsThreeMember 2017-06-30 0001438943 vbio:StockOptionsFourMember 2017-06-30 0001438943 vbio:StockOptionsFiveMember 2017-06-30 0001438943 vbio:StockOptionsSixMember 2017-06-30 0001438943 vbio:StockOptionsFiveMember us-gaap:MaximumMember 2017-06-30 0001438943 vbio:StockOptionsFiveMember us-gaap:MinimumMember 2017-06-30 0001438943 vbio:StockOptionsOneMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsTwoMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsThreeMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsFourMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsFiveMember us-gaap:MaximumMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsFiveMember us-gaap:MinimumMember 2017-04-01 2017-06-30 0001438943 us-gaap:CommonStockMember 2017-03-31 0001438943 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001438943 us-gaap:RetainedEarningsMember 2017-03-31 0001438943 vbio:StockOptionsSixMember us-gaap:MinimumMember 2017-06-30 0001438943 vbio:StockOptionsSixMember us-gaap:MaximumMember 2017-06-30 0001438943 vbio:StockOptionsSixMember us-gaap:MinimumMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsSixMember us-gaap:MaximumMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsSevenMember 2017-06-30 0001438943 vbio:StockOptionsSevenMember us-gaap:MinimumMember 2017-06-30 0001438943 vbio:StockOptionsSevenMember us-gaap:MaximumMember 2017-06-30 0001438943 vbio:StockOptionsSevenMember us-gaap:MinimumMember 2017-04-01 2017-06-30 0001438943 vbio:StockOptionsSevenMember us-gaap:MaximumMember 2017-04-01 2017-06-30 0001438943 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001438943 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0001438943 vbio:OneConsultantsMember 2017-04-01 2017-06-30 0001438943 us-gaap:SubsequentEventMember vbio:SecuritiesPurchaseAgreementMember 2017-07-25 2017-07-26 0001438943 2017-08-09 0001438943 2017-06-30 0001438943 2016-04-01 2016-06-30 0001438943 us-gaap:CommonStockMember 2017-04-01 2017-06-30 0001438943 us-gaap:CommonStockMember 2017-06-30 0001438943 us-gaap:AdditionalPaidInCapitalMember 2017-04-01 2017-06-30 0001438943 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001438943 us-gaap:RetainedEarningsMember 2017-04-01 2017-06-30 0001438943 us-gaap:RetainedEarningsMember 2017-06-30 0001438943 2016-06-30 0001438943 vbio:JulyTwoThousandSeventeenMember vbio:InvestorsMember 2017-04-01 2017-06-30 0001438943 2016-04-01 2017-03-31 0001438943 us-gaap:MinimumMember 2017-04-01 2017-06-30 0001438943 us-gaap:MaximumMember 2017-04-01 2017-06-30 0001438943 us-gaap:RestrictedStockMember 2017-04-01 2017-06-30 0001438943 us-gaap:RestrictedStockMember 2017-06-30 0001438943 us-gaap:SubsequentEventMember vbio:SecuritiesPurchaseAgreementMember 2017-07-26 0001438943 us-gaap:SubsequentEventMember 2017-07-01 2017-07-31 0001438943 vbio:JulyTwoThousandSeventeenMember vbio:InvestorsMember 2017-06-30 0001438943 vbio:LeaseAgreementMember vbio:OneWorldRanchesMember 2017-04-28 2017-05-01 xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:USD false --03-31 2017-06-30 10-Q Smaller Reporting Company Vitality Biopharma, Inc. 373696 306783 34500 22000 19198 25332 342540 342540 1175022 558992 95433 1152766 530602 20481 -622164 -74952 2.79 2.79 2.00 7950000 333334 333334 0.001 0.001 1000000000 1000000000 22215180 22265180 22215180 22265180 22214 22264 35014 0.00 0.00 P3Y P1Y P1Y P3Y 1.27 1.25 0.0019 0.0114 0.0155 -66913 -11984 -12500 6900 6134 8807 363 100000 800654 745853 265030 -622164 -339982 -1106353 -439405 -1106353 7500 6900 2300 1436170 1436170 427708 37500 130000 75000 235000 123334 45834 1006876 1.50 30000 2820489 1710821 153000 130000 10000 647500 123334 45834 2820489 1.27 1.27 0.50 0.96 10.00 1.50 2.79 2.00 3.10 3.80 4.00 4.70 1.79 22215180 22265180 374368 22214 18088093 -17735939 -186861 22264 18633167 -18842292 50000 50000 2650000 666667 666667 100000 10000 50 99950 80278 0.50 0.96 10.00 1.50 2.79 2.00 3.10 3.80 4.00 4.70 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the Company&#8217;s stock option activity during the three months ended June 30, 2017 is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance outstanding at March 31, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.27</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance outstanding at June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.27</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance exercisable at June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,006,876</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A summary of the Company&#8217;s stock options outstanding and exercisable as of June 30, 2017 is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Average Grant-</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>date Stock Price</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Outstanding, June 30, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,710,821</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">153,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">130,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10.00</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">647,500</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">123,334</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">45,834</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercisable, June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">427,708</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">37,500</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">130,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10.00</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,5000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">235,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">123,334</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">45,834</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,006,876</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> VBIO 23265180 Q1 240791 265403 P1Y P24M 1.2691 0.0220 0.00 P5Y -342540 -39905 165030 952466 372421 372421 2017 18088093 18633167 -17735939 -18842292 1175022 558992 24613 3058 3058 -102584 -24000 100000 3192910 9702713 372421 2820489 892500 10595213 3050000 102504 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Vitality Biopharma, Inc. (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;), was incorporated in the State of Nevada on June 29, 2007. The Company&#8217;s fiscal year end is March 31.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In 2015, the Company developed a new class of cannabinoids known as cannabosides, which were discovered through application of the Company&#8217;s proprietary enzymatic bioprocessing technologies originally developed for stevia sweeteners. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2017, the Company incurred a net loss of $1,106,353 and used cash in operating activities of $622,164. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2017 we have sufficient funds to operate the business for the next 6 months. In July 2017, the Company issued an aggregate of 666,667 shares of our common stock and warrants to purchase 333,334 of our common stock to certain investors for net proceeds of approximately $995,000. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders&#8217; ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Basis of Presentation of Unaudited Condensed Financial Information</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited condensed financial statements of the Company for the three months ended June 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#8217;s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2017 was derived from the Company&#8217;s audited financial statements as of and for the year ended March 31, 2017 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 28, 2017. These financial statements should be read in conjunction with that report.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Financial Assets and Liabilities Measured at Fair Value</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 58px; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Quoted prices in active markets for identical assets or liabilities.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Unobservable inputs based on the Company&#8217;s assumptions.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of the derivative liabilities of $265,403 and $240,791 at June 30, 2017 and March 31, 2017, respectively, were valued using Level 2 inputs.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Derivative Financial Instruments</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2017, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock-Based Compensation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (&#8220;ASC&#8221;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company&#8217;s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company periodically issues unvested (&#8220;restricted&#8221;) shares of its common stock to employees as equity incentives. The Company&#8217;s restricted stock vests upon the satisfaction of a recipient&#8217;s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company&#8217;s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basic and Diluted Loss Per Share</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Three months ended</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2016</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">892,500</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,421</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9,702,713</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,192,910</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,595,213</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Research and Development</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company&#8217;s treatments and product candidates. Research and development costs are expensed as incurred.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent Accounting Pronouncements</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has recently issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, and ASU 2017-05, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. The standard can be adopted either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is currently in the process of analyzing the information necessary to determine the impact of adopting this new guidance on its financial position, results of operations, and cash flows. The Company will adopt the provisions of this statement in the quarter beginning April 1, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2017, the FASB issued ASU 2017-11, <i>Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.</i> ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity&#8217;s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 in the third quarter of 2017. The adoption of ASU 2017-11 is not expected to have an impact on the Company&#8217;s financial statements and related disclosures because the conversion feature of the Company&#8217;s warrants have features other than down round provisions that require current accounting treatment and classification.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future financial statements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. DERIVATIVE LIABILITY</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2015, the Company issued certain warrants which included an anti-dilution provision that allows for the automatic reset of the exercise price of the warrants upon future sale of the Company&#8217;s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants. In addition, the Company determined that the warrants can be settled for cash at the holders&#8217; option in a future fundamental transaction, as defined. As a result of the anti-dilution and fundamental transaction provisions, the Company determined that the conversion feature of the warrants should be separated from the host contract, be recognized as a derivative liability, and re-measured at each reporting period with the change in value reported in the statement of operations.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At March 31, 2017, the balance of the derivative liabilities was $240,791. During the three months ended June 30, 2017, the Company recorded an increase in derivative liability of $24,613. At June 30, 2017, the balance of the derivative liabilities was $265,403.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2017 and March 31, 2017, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2017</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion feature:</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.14-1.55</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.19</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">127</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">125</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life (in years)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1 to 3 years</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1 to 3 years</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value:</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion feature</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">265,403</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">240,791</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>3. STOCKHOLDERS&#8217; EQUITY (DEFICIENCY)</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Common stock issued to employees with vesting terms</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has issued shares of common stock to employees and directors that vest over time. The fair value of these stock awards are based on the market price of the Company&#8217;s common stock on the dates granted, and are amortized over vesting terms ranging up to three years.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At March 31, 2017, the accumulated vested balance of stock awards was $952,466. During the three months ended June 30, 2017, we recorded expense related to the fair value of stock awards that vested of $102,504. At June 30, 2017, the amount of unvested compensation related to these awards is approximately $307,750, and will be recorded as expense over 1 year.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient&#8217;s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes restricted common stock activity:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-vested shares, April 1, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,436,170</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-vested shares, June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,436,170</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common stock issued for services</i></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three months ended June 30, 2017, the Company issued a total of 50,000 shares of common stock to one consultant as payment for services and recorded expenses of $100,000 based on the fair value of the Company&#8217;s common stock at the issuance dates.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>4. STOCK OPTIONS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the Company&#8217;s stock option activity during the three months ended June 30, 2017 is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance outstanding at March 31, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.27</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance outstanding at June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.27</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance exercisable at June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,006,876</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A summary of the Company&#8217;s stock options outstanding and exercisable as of June 30, 2017 is as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Options</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td> <td style="text-align: center; line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>Average Grant-</b></font><br /> <font style="font: 10pt Times New Roman, Times, Serif"><b>date Stock Price</b></font></td> <td style="text-align: center; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Outstanding, June 30, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,710,821</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">153,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">130,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10.00</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">647,500</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">123,334</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">45,834</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercisable, June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">427,708</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.50</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">37,500</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.96</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">130,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.00</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10.00</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,5000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.50</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">235,000</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.00 &#8211; 2.79</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">123,334</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.10 &#8211; 3.80</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">45,834</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70 </font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.00 &#8211; 4.70</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,006,876</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three months ended June 30, 2017, we expensed total stock-based compensation related to stock options of $342,540, and the remaining unamortized cost of the outstanding stock-based awards at June 30, 2017 was approximately $740,000. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years. At June 30, 2017, the 2,820,489 outstanding stock options had an intrinsic value of approximately $3,050,000.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>5. WARRANTS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">At June 30, 2017, warrants to purchase common shares were outstanding as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted </font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Average Exercise Price</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,421</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance outstanding and exercisable at June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,421</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>6. RELATED PARTY OBLIGATIONS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #222222">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #222222">On April 23, 2012, the Company entered into a lease agreement with One World Ranches, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Company&#8217;s Board of Directors, and his wife, to rent the space being used as the Company&#8217;s principal office and laboratory facility. The original term of the lease was from May 1, 2012 to May 1, 2017. In May 2017, the Company extended the lease through May 1, 2020. Our rent payments thereunder were $2,300 per month until May 1, 2017 and increased to $2,600 per month on May 1, 2017. Aggregate payments under the lease for the three months ended June 30, 2017 and 2016 were $7,500 and $6,900, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>7. COMMITMENTS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 19, 2016, we filed a resale registration statement on Form S-1 (&#8220;Form S-1&#8221;) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. The document requests were primarily in connection with this matter. We have complied with all document requests and the Company&#8217;s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of December 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of June 30, 2017, we had accrued approximately $44,000 in legal fees related to the SEC examination.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>8. SUBSEQUENT EVENTS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #222222">On July 26, 2017, the Company entered into a Securities Purchase Agreement with the purchasers identified therein providing for the issuance and sale by the Company to the purchasers, of an aggregate of 666,667 shares of the Company&#8217;s common stock (collectively, the &#8220;Shares&#8221;) and Warrants to purchase up to an aggregate of 333,334 shares of the Company&#8217;s common stock (the &#8220;Warrants&#8221;), at a price of $1.50 per share (the &#8220;Offering&#8221;). The Warrants have an exercise price of $2.00 per share, are exercisable immediately, expire on the three year anniversary of the date of issuance, and may be exercised on a cashless basis. The Offering closed on July 28, 2017. The aggregate proceeds to the Company from the sale of the Shares and Warrants was approximately $995,000.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #222222">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2017, we issued options to purchase 30,000 shares of our common stock to a consultant with a fair value of $50,127 at grant date. These options have an exercise price of $1.79 per share and expire ten years from the date of issuance. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.91%, (ii) discount rate of 2.20 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The fair value of the option grants to the consultants will be recalculated each quarter and will be amortized over 24 months as the options vest based on their fair value at the end of each quarterly reporting period.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2017, the Company incurred a net loss of $1,106,353 and used cash in operating activities of $622,164. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2017 we have sufficient funds to operate the business for the next 6 months. In July 2017, the Company issued an aggregate of 666,667 shares of our common stock and warrants to purchase 333,334 of our common stock to certain investors for net proceeds of approximately $995,000. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders&#8217; ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of Estimates</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Financial Assets and Liabilities Measured at Fair Value</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 58px; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Quoted prices in active markets for identical assets or liabilities.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%">&#160;</td> <td style="text-align: justify; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Unobservable inputs based on the Company&#8217;s assumptions.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of the derivative liabilities of $265,403 and $240,791 at June 30, 2017 and March 31, 2017, respectively, were valued using Level 2 inputs.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management&#8217;s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Derivative Financial Instruments</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2017, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Stock-Based Compensation</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (&#8220;ASC&#8221;), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company&#8217;s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company periodically issues unvested (&#8220;restricted&#8221;) shares of its common stock to employees as equity incentives. The Company&#8217;s restricted stock vests upon the satisfaction of a recipient&#8217;s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company&#8217;s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basic and Diluted Loss Per Share</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Three months ended</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2016</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">892,500</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,421</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9,702,713</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,192,910</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,595,213</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Research and Development</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company&#8217;s treatments and product candidates. Research and development costs are expensed as incurred.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent Accounting Pronouncements</u></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has recently issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, and ASU 2017-05, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. The standard can be adopted either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is currently in the process of analyzing the information necessary to determine the impact of adopting this new guidance on its financial position, results of operations, and cash flows. The Company will adopt the provisions of this statement in the quarter beginning April 1, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2017, the FASB issued ASU 2017-11, <i>Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.</i> ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity&#8217;s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 in the third quarter of 2017. The adoption of ASU 2017-11 is not expected to have an impact on the Company&#8217;s financial statements and related disclosures because the conversion feature of the Company&#8217;s warrants have features other than down round provisions that require current accounting treatment and classification.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company&#8217;s present or future financial statements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Three months ended</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2016</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,820,489</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">892,500</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,421</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9,702,713</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,192,910</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,595,213</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2017 and March 31, 2017, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>June 30, 2017</b></font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2017</b></font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion feature:</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.14-1.55</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.19</font></td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">127</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">125</font></td> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life (in years)</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1 to 3 years</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1 to 3 years</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected dividend yield</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value:</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Conversion feature</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">265,403</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">240,791</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes restricted common stock activity:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-vested shares, April 1, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 15%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,436,170</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-vested shares, June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,436,170</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">At June 30, 2017, warrants to purchase common shares were outstanding as follows:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Shares</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted </font><br /> <font style="font: 10pt Times New Roman, Times, Serif">Average Exercise Price</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 68%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2017</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,421</font></td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%">&#160;</td> <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td> <td style="width: 1%; line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 115%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance outstanding and exercisable at June 30, 2017</font></td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,421</font></td> <td style="line-height: 115%">&#160;</td> <td style="line-height: 115%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.79</font></td> <td style="line-height: 115%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 240791 265403 50127 995000 995000 6557 21258 20486 25119 27043 46377 1088298 445089 7500 6900 407009 110315 673789 327874 -1081741 -423831 -24612 -15574 621 22255290 10069358 -0.05 -0.04 102584 102584 -24612 -14953 -558 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Basis of Presentation of Unaudited Condensed Financial Information</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited condensed financial statements of the Company for the three months ended June 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#8217;s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2017 was derived from the Company&#8217;s audited financial statements as of and for the year ended March 31, 2017 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on June 28, 2017. These financial statements should be read in conjunction with that report.</p> The original term of the lease was from May 1, 2012 to May 1, 2017. In May 2017, the Company extended the lease through May 1, 2020. 151667 151667 740000 P2Y 0.50 0.96 1.00 1.50 2.79 2.00 3.10 3.80 4.00 4.70 0.50 0.96 1.00 1.50 2.79 2.00 3.10 3.80 4.00 4.70 2017-05-01 2600 44000 1.50 0001438943 307750 EX-101.SCH 6 vbio-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Operations and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders' Equity (Deficiency) link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Obligations link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders' Equity (Deficiency) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Derivative Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholders' Equity (Deficiency) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock Options - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Warrants - Summary of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Related Party Transactions and Lease Obligations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vbio-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 vbio-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 vbio-20170630_lab.xml XBRL LABEL FILE Antidilutive Securities [Axis] Warrants [Member] Range [Axis] Maximum [Member] Minimum [Member] Types Of Leases [Axis] Lease Agreement [Member] Related Party [Axis] One World Ranches [Member] Class of Stock [Axis] Restricted Stock [Member] Award Type [Axis] Stock Options One [Member] Stock Options Two [Member] Stock Options Three [Member] Stock Options Four [Member] Stock Options Five [Member] Stock Options Six [Member] Equity Components [Axis] Common Stock [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Stock Options Seven [Member] Options [Member] Title of Individual [Axis] One Consultants [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Securities Purchase Agreement [Member] Additional Paid-In Capital [Member] Report Date [Axis] July 2017 [Member] Investors [Member] Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash Accounts receivable, net Prepaid expenses Total Assets Liabilities and Stockholders’ Equity (Deficiency) Current Liabilities Accounts payable and accrued liabilities Accrued compensation - officers and directors Accounts payable - related party Derivative liability Total liabilities Stockholders’ Equity (Deficiency) Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 22,265,180 and 22,215,180 shares issued and outstanding, respectively Additional paid-in-capital Accumulated deficit Total stockholders’ equity (deficiency) Total liabilities and stockholders’ equity (deficiency) Balance Sheet Related Disclosures [Abstract] Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of goods sold Gross profit Operating expenses: General and administrative Research and development Rent - related party Total operating expenses Loss from operations Other income (expenses) Change in fair value of derivative liability Interest expense Total other expenses, net Net loss Net loss per common share Basic and diluted Weighted average number of common shares outstanding Basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Fair value of vested restricted common stock Fair value of vested stock options Fair value of common stock issued for services Fair value of common stock issued for services, shares Net Loss Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities Fair value of vested stock options Amortization of common stock issued to employees with vesting terms Fair value of common stock issued for services Change in fair value of derivative liability Fair value of vested warrants granted to employees Changes in operating assets and liabilities: Accounts receivable Deposit Accounts payable and accrued liabilities Accounts payable - related party Net cash used in operating activities Financing activities Proceeds from common stock issuable Proceeds from sale of common stock, net Net cash provided by financing activities Net decrease in cash Cash and cash equivalents - beginning of period Cash and cash equivalent - end of period Supplemental disclosure of cash flow information: Cash paid during the period for: Interest Income taxes Non-cash activities: Extinguishment of derivative liability Accounting Policies [Abstract] Business Operations and Summary of Significant Accounting Policies Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Liability Stockholders' Equity Note [Abstract] Stockholders' Equity (Deficiency) Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Options Warrants and Rights Note Disclosure [Abstract] Warrants Related Party Transactions [Abstract] Related Party Obligations Commitments and Contingencies Disclosure [Abstract] Commitments Subsequent Events [Abstract] Subsequent Events Going Concern Basis of Presentation of Unaudited Condensed Financial Information Use of Estimates Financial Assets and Liabilities Measured at Fair Value Derivative Financial Instruments Stock-Based Compensation Basic and Diluted Loss Per Share Research and Development Recent Accounting Pronouncements Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Valuation Assumptions for Derivative Liabilities Schedule of Nonvested Restricted Stock Unit Activity Summary of Stock Option Activity Schedule of Stock Options Outstanding and Exercisable Summary of Warrant Activity Net loss Net cash used in operating activities Stock issued during period, shares, new issues Warrants to purchase common stock Proceeds from issuance of warrants Fair value of derivative liabilities Antidilutive securities excluded from computation of earnings per share Derivative liabilities Increase in derivative liabilities Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Risk-free interest rate Expected volatility Expected life (in years) Expected dividend yield Fair Value of Derivative Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Class of Warrant or Right [Axis] Accumulated vested balance of stock Fair value of stock awards that vested Stock-based compensation expense not yet recognized Stock-based compensation unvested compensation related to awards period Common stock issued for services, shares Common stock issued for services Non-vested shares, Beginning Balance Granted Vested Forfeited Non-vested shares, Ending Balance Stock-based compensation Unamortized cost of outstanding stock-based awards Weighted average remaining vesting period Number of stock options outstanding, shares Options outstanding, intrinsic value Shares, beginning balance outstanding Shares, Granted Shares, Exercised Shares, Expired Shares, Cancelled Shares, ending balance outstanding Shares, Balance exercisable Weighted Average Exercise Price, beginning balance outstanding Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Expired Weighted Average Exercise Price, Cancelled Weighted Average Exercise Price, ending balance outstanding Weighted Average Exercise Price, Balance exercisable Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Number of options outstanding Weighted average exercise price, options outstanding Weighted average grant-date stock price, options outstanding Number of options exercisable Weighted average exercise price, options exercisable Weighted average grant-date stock price, options exercisable Shares, Outstanding Beginning Balance Shares, Granted Shares, Exercised Shares, Expired Shares, outstanding and exercisable Balance Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Expired/Cancelled Weighted Average Exercise Price, Outstanding and Ending Balance Schedule of Operating Leased Assets [Table] Operating Leased Assets [Line Items] Lease description Payments for rent per month Lease expiration date Increase payment for rent per month Operating leases, net rent expense Accrued legal fees Common stock issuable upon exercise of warrants Stock issued price per share Exercise price of warrants Aggregate proceeds from sale of the shares and warrants Number of option issued to purchase common stock Fair value of stock option grants Exercise price, option granted Stock option, volatility rate Stock option, discount rate Stock option, expected dividend yield Stock option, expected term Stock option, award vesting period Accumulated vested balance of stock. Carlson Lease [Member] Common Stock, Issuable [Member] Employees [Member] The fair value of cost associated with the extinguishment of warrant derivative liabilities being converted in a noncash (or part noncash transaction). "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Going Concern [Policy Text Block] License Agreements [Member] Non Employees [Member] One Consultants [Member] Percipio Biosciences Inc [Member] Securities Purchase Agreement [Member] Stock Options Eight [Member] Stock Options Five [Member] Stock Options Four [Member] Stock Options One [Member] Stock Options Seven [Member] Stock Options Six [Member] Stock Options Three [Member] Stock Options Two [Member] Two Consultants [Member] Types Of Leases [Axis] Types Of Leases [Domain] The entire disclosure for warrants issued during the period [Text Block] Number of warrants exercised in period. Weighted average exercise price of warrants exercised in period. Number of warrants expired in period. Weighted Average Exercise Price, Expired. Number of warrants granted in period. Weighted average exercise price of warrants granted in period. Per share value of options outstanding and currently exercisable under the stock option plan. Amortization of common stock issued to employees with vesting terms. Securities Purchase Agreement [Member] Four Consultants [Member] Seven Consultants [Member] Five Consultants [Member] Asset Purchase Agreement [Member] Mr. Dong and Mr. Guo [Member] Warrants [Member] State [Member] Increase payment for rent per month. Lease description. July 2017 [Member] Investors [Member] Lease Agreement [Member] One World Ranches [Member] Assets [Default Label] Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense, Other Nonoperating Income (Expense) Weighted Average Number of Shares Outstanding, Basic and Diluted Shares, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value AmortizationOfCommonStockIssuedToEmployeesWithVestingTerms Issuance of Stock and Warrants for Services or Claims Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable, Related Parties Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash, Period Increase (Decrease) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Class of Warrant or Right, Outstanding Warrants Granted In Period Warrants Exercised In Period Warrants Granted Period In Weighted Exercise Price Warrants Exercised Period In Weighted Exercise Price EX-101.PRE 10 vbio-20170630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document And Entity Information - shares
3 Months Ended
Jun. 30, 2017
Aug. 09, 2017
Document And Entity Information [Abstract]    
Entity Registrant Name Vitality Biopharma, Inc.  
Entity Central Index Key 0001438943  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Amendment Flag false  
Current Fiscal Year End Date --03-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   23,265,180
Trading Symbol VBIO  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2017  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Balance Sheets - USD ($)
Jun. 30, 2017
Mar. 31, 2017
Current Assets    
Cash $ 530,602 $ 1,152,766
Accounts receivable, net 25,332 19,198
Prepaid expenses 3,058 3,058
Total Assets 558,992 1,175,022
Current Liabilities    
Accounts payable and accrued liabilities 306,783 373,696
Accrued compensation - officers and directors 151,667 151,667
Accounts payable - related party 22,000 34,500
Derivative liability 265,403 240,791
Total liabilities 745,853 800,654
Stockholders’ Equity (Deficiency)    
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 22,265,180 and 22,215,180 shares issued and outstanding, respectively 22,264 22,214
Additional paid-in-capital 18,633,167 18,088,093
Accumulated deficit (18,842,292) (17,735,939)
Total stockholders’ equity (deficiency) (186,861) 374,368
Total liabilities and stockholders’ equity (deficiency) $ 558,992 $ 1,175,022
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2017
Mar. 31, 2017
Balance Sheet Related Disclosures [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 22,265,180 22,215,180
Common stock, shares outstanding 22,265,180 22,215,180
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]    
Revenue $ 27,043 $ 46,377
Cost of goods sold 20,486 25,119
Gross profit 6,557 21,258
Operating expenses:    
General and administrative 673,789 327,874
Research and development 407,009 110,315
Rent - related party 7,500 6,900
Total operating expenses 1,088,298 445,089
Loss from operations (1,081,741) (423,831)
Other income (expenses)    
Change in fair value of derivative liability (24,612) (14,953)
Interest expense (621)
Total other expenses, net (24,612) (15,574)
Net loss $ (1,106,353) $ (439,405)
Net loss per common share    
Basic and diluted $ (0.05) $ (0.04)
Weighted average number of common shares outstanding    
Basic and diluted 22,255,290 10,069,358
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) - 3 months ended Jun. 30, 2017 - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Total
Balance at Mar. 31, 2017 $ 22,214 $ 18,088,093 $ (17,735,939) $ 374,368
Balance, shares at Mar. 31, 2017 22,215,180      
Fair value of vested restricted common stock 102,584 102,584
Fair value of vested stock options 342,540 342,540
Fair value of common stock issued for services $ 50 99,950 100,000
Fair value of common stock issued for services, shares 50,000      
Net Loss (1,106,353) (1,106,353)
Balance at Jun. 30, 2017 $ 22,264 $ 18,633,167 $ (18,842,292) $ (186,861)
Balance, shares at Jun. 30, 2017 22,265,180      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Operating activities    
Net loss $ (1,106,353) $ (439,405)
Adjustments to reconcile net loss to net cash used in operating activities    
Fair value of vested stock options 342,540 39,905
Amortization of common stock issued to employees with vesting terms 102,584 24,000
Fair value of common stock issued for services 100,000
Change in fair value of derivative liability 24,612 14,953
Fair value of vested warrants granted to employees 35,014
Changes in operating assets and liabilities:    
Accounts receivable (6,134) (8,807)
Deposit (558)
Accounts payable and accrued liabilities (66,913) (11,984)
Accounts payable - related party (12,500) 6,900
Net cash used in operating activities (622,164) (339,982)
Financing activities    
Proceeds from common stock issuable 100,000
Proceeds from sale of common stock, net 165,030
Net cash provided by financing activities 265,030
Net decrease in cash (622,164) (74,952)
Cash and cash equivalents - beginning of period 1,152,766 95,433
Cash and cash equivalent - end of period 530,602 20,481
Cash paid during the period for:    
Interest 363
Income taxes
Non-cash activities:    
Extinguishment of derivative liability $ 80,278
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Operations and Summary of Significant Accounting Policies
3 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Business Operations and Summary of Significant Accounting Policies

1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31.

 

In 2015, the Company developed a new class of cannabinoids known as cannabosides, which were discovered through application of the Company’s proprietary enzymatic bioprocessing technologies originally developed for stevia sweeteners. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides.

 

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2017, the Company incurred a net loss of $1,106,353 and used cash in operating activities of $622,164. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2017 we have sufficient funds to operate the business for the next 6 months. In July 2017, the Company issued an aggregate of 666,667 shares of our common stock and warrants to purchase 333,334 of our common stock to certain investors for net proceeds of approximately $995,000. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

 

We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

  

Basis of Presentation of Unaudited Condensed Financial Information

 

The unaudited condensed financial statements of the Company for the three months ended June 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2017 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 28, 2017. These financial statements should be read in conjunction with that report.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.

 

Financial Assets and Liabilities Measured at Fair Value

 

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:

 

Level 1 Quoted prices in active markets for identical assets or liabilities.
   
Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
   
Level 3 Unobservable inputs based on the Company’s assumptions.

 

The fair value of the derivative liabilities of $265,403 and $240,791 at June 30, 2017 and March 31, 2017, respectively, were valued using Level 2 inputs.

 

The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2017, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

  

Stock-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.

 

Basic and Diluted Loss Per Share

 

Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

 

    Three months ended  
    June 30, 2017     June 30, 2016  
Options     2,820,489       892,500  
Warrants     372,421       9,702,713  
Total     3,192,910       10,595,213  

 

Research and Development

 

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.

  

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has recently issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, and ASU 2017-05, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. The standard can be adopted either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is currently in the process of analyzing the information necessary to determine the impact of adopting this new guidance on its financial position, results of operations, and cash flows. The Company will adopt the provisions of this statement in the quarter beginning April 1, 2018.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.

 

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 in the third quarter of 2017. The adoption of ASU 2017-11 is not expected to have an impact on the Company’s financial statements and related disclosures because the conversion feature of the Company’s warrants have features other than down round provisions that require current accounting treatment and classification.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
Derivative Liability
3 Months Ended
Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Liability

2. DERIVATIVE LIABILITY

 

In May 2015, the Company issued certain warrants which included an anti-dilution provision that allows for the automatic reset of the exercise price of the warrants upon future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants. In addition, the Company determined that the warrants can be settled for cash at the holders’ option in a future fundamental transaction, as defined. As a result of the anti-dilution and fundamental transaction provisions, the Company determined that the conversion feature of the warrants should be separated from the host contract, be recognized as a derivative liability, and re-measured at each reporting period with the change in value reported in the statement of operations.

 

At March 31, 2017, the balance of the derivative liabilities was $240,791. During the three months ended June 30, 2017, the Company recorded an increase in derivative liability of $24,613. At June 30, 2017, the balance of the derivative liabilities was $265,403.

 

At June 30, 2017 and March 31, 2017, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:

 

    June 30, 2017     March 31, 2017  
Conversion feature:                
Risk-free interest rate     1.14-1.55 %     0.19 %
Expected volatility     127 %     125 %
Expected life (in years)     1 to 3 years       1 to 3 years  
Expected dividend yield            
                 
Fair Value:                
Conversion feature   $ 265,403     $ 240,791  

 

The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Deficiency)
3 Months Ended
Jun. 30, 2017
Stockholders' Equity Note [Abstract]  
Stockholders' Equity (Deficiency)

3. STOCKHOLDERS’ EQUITY (DEFICIENCY)

 

Common stock issued to employees with vesting terms

 

The Company has issued shares of common stock to employees and directors that vest over time. The fair value of these stock awards are based on the market price of the Company’s common stock on the dates granted, and are amortized over vesting terms ranging up to three years.

 

At March 31, 2017, the accumulated vested balance of stock awards was $952,466. During the three months ended June 30, 2017, we recorded expense related to the fair value of stock awards that vested of $102,504. At June 30, 2017, the amount of unvested compensation related to these awards is approximately $307,750, and will be recorded as expense over 1 year.

  

Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement.

 

The following table summarizes restricted common stock activity:

 

    Number of Shares  
Non-vested shares, April 1, 2017     1,436,170  
Granted      
Vested      
Forfeited      
Non-vested shares, June 30, 2017     1,436,170  

 

Common stock issued for services

 

During the three months ended June 30, 2017, the Company issued a total of 50,000 shares of common stock to one consultant as payment for services and recorded expenses of $100,000 based on the fair value of the Company’s common stock at the issuance dates.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Options
3 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Options

4. STOCK OPTIONS

 

A summary of the Company’s stock option activity during the three months ended June 30, 2017 is as follows:

 

    Shares     Weighted
Average
Exercise Price
 
Balance outstanding at March 31, 2017     2,820,489     $ 1.27  
Granted              
Exercised              
Expired              
Cancelled              
Balance outstanding at June 30, 2017     2,820,489     $ 1.27  
Balance exercisable at June 30, 2017     1,006,876     $ 1.50  

 

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:

 

    Number of
Options
    Weighted
Average
Exercise Price
    Weighted
Average Grant-
date Stock Price
 
Options Outstanding, June 30, 2017     1,710,821     $ 0.50     $ 0.50  
      153,000     $ 0.96     $ 0.96  
      130,000     $ 1.00     $ 10.00  
      10,000     $ 1.50     $ 1.50  
      647,500     $ 2.00 – 2.79     $ 2.00 – 2.79  
      123,334     $ 3.10 – 3.80     $ 3.10 – 3.80  
      45,834     $ 4.00 – 4.70     $ 4.00 – 4.70  
      2,820,489                  
Options Exercisable, June 30, 2017     427,708     $ 0.50     $ 0.50  
      37,500     $ 0.96     $ 0.96  
      130,000     $ 1.00     $ 10.00  
      7,5000     $ 1.50     $ 1.50  
      235,000     $ 2.00 – 2.79     $ 2.00 – 2.79  
      123,334     $ 3.10 – 3.80     $ 3.10 – 3.80  
      45,834     $ 4.00 – 4.70     $ 4.00 – 4.70  
      1,006,876                  

 

During the three months ended June 30, 2017, we expensed total stock-based compensation related to stock options of $342,540, and the remaining unamortized cost of the outstanding stock-based awards at June 30, 2017 was approximately $740,000. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years. At June 30, 2017, the 2,820,489 outstanding stock options had an intrinsic value of approximately $3,050,000.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Warrants
3 Months Ended
Jun. 30, 2017
Warrants and Rights Note Disclosure [Abstract]  
Warrants

5. WARRANTS

 

At June 30, 2017, warrants to purchase common shares were outstanding as follows:

 

    Shares     Weighted
Average Exercise Price
 
Balance at March 31, 2017     372,421     $ 2.79  
Granted            
Exercised            
Expired           $  
Balance outstanding and exercisable at June 30, 2017     372,421     $ 2.79  

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Obligations
3 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]  
Related Party Obligations

6. RELATED PARTY OBLIGATIONS

 

On April 23, 2012, the Company entered into a lease agreement with One World Ranches, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Company’s Board of Directors, and his wife, to rent the space being used as the Company’s principal office and laboratory facility. The original term of the lease was from May 1, 2012 to May 1, 2017. In May 2017, the Company extended the lease through May 1, 2020. Our rent payments thereunder were $2,300 per month until May 1, 2017 and increased to $2,600 per month on May 1, 2017. Aggregate payments under the lease for the three months ended June 30, 2017 and 2016 were $7,500 and $6,900, respectively.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments
3 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments

7. COMMITMENTS

 

On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. The document requests were primarily in connection with this matter. We have complied with all document requests and the Company’s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of December 2017.

 

As of June 30, 2017, we had accrued approximately $44,000 in legal fees related to the SEC examination.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events
3 Months Ended
Jun. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events

8. SUBSEQUENT EVENTS

 

On July 26, 2017, the Company entered into a Securities Purchase Agreement with the purchasers identified therein providing for the issuance and sale by the Company to the purchasers, of an aggregate of 666,667 shares of the Company’s common stock (collectively, the “Shares”) and Warrants to purchase up to an aggregate of 333,334 shares of the Company’s common stock (the “Warrants”), at a price of $1.50 per share (the “Offering”). The Warrants have an exercise price of $2.00 per share, are exercisable immediately, expire on the three year anniversary of the date of issuance, and may be exercised on a cashless basis. The Offering closed on July 28, 2017. The aggregate proceeds to the Company from the sale of the Shares and Warrants was approximately $995,000.

 

In July 2017, we issued options to purchase 30,000 shares of our common stock to a consultant with a fair value of $50,127 at grant date. These options have an exercise price of $1.79 per share and expire ten years from the date of issuance. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.91%, (ii) discount rate of 2.20 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The fair value of the option grants to the consultants will be recalculated each quarter and will be amortized over 24 months as the options vest based on their fair value at the end of each quarterly reporting period.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Operations and Summary of Significant Accounting Policies (Policies)
3 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Going Concern

Going Concern

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended June 30, 2017, the Company incurred a net loss of $1,106,353 and used cash in operating activities of $622,164. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

 

The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that as of June 30, 2017 we have sufficient funds to operate the business for the next 6 months. In July 2017, the Company issued an aggregate of 666,667 shares of our common stock and warrants to purchase 333,334 of our common stock to certain investors for net proceeds of approximately $995,000. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, licensing or acquiring new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

 

We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

Basis of Presentation of Unaudited Condensed Financial Information

Basis of Presentation of Unaudited Condensed Financial Information

 

The unaudited condensed financial statements of the Company for the three months ended June 30, 2017 and 2016 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2017 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2017 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 28, 2017. These financial statements should be read in conjunction with that report.

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.

Financial Assets and Liabilities Measured at Fair Value

Financial Assets and Liabilities Measured at Fair Value

 

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:

 

Level 1 Quoted prices in active markets for identical assets or liabilities.
   
Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
   
Level 3 Unobservable inputs based on the Company’s assumptions.

 

The fair value of the derivative liabilities of $265,403 and $240,791 at June 30, 2017 and March 31, 2017, respectively, were valued using Level 2 inputs.

 

The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Derivative Financial Instruments

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the June 30, 2017, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.

Stock-Based Compensation

Stock-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.

Basic and Diluted Loss Per Share

Basic and Diluted Loss Per Share

 

Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

 

    Three months ended  
    June 30, 2017     June 30, 2016  
Options     2,820,489       892,500  
Warrants     372,421       9,702,713  
Total     3,192,910       10,595,213  

Research and Development

Research and Development

 

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has recently issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, ASU 2016-20, and ASU 2017-05, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. The standard can be adopted either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company is currently in the process of analyzing the information necessary to determine the impact of adopting this new guidance on its financial position, results of operations, and cash flows. The Company will adopt the provisions of this statement in the quarter beginning April 1, 2018.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.

 

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company plans to adopt ASU 2017-11 in the third quarter of 2017. The adoption of ASU 2017-11 is not expected to have an impact on the Company’s financial statements and related disclosures because the conversion feature of the Company’s warrants have features other than down round provisions that require current accounting treatment and classification.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Operations and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Antidilutive Securities Excluded from Computation of Earnings Per Share

The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:

 

    Three months ended  
    June 30, 2017     June 30, 2016  
Options     2,820,489       892,500  
Warrants     372,421       9,702,713  
Total     3,192,910       10,595,213  

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Derivative Liability (Tables)
3 Months Ended
Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Valuation Assumptions for Derivative Liabilities

At June 30, 2017 and March 31, 2017, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions:

 

    June 30, 2017     March 31, 2017  
Conversion feature:                
Risk-free interest rate     1.14-1.55 %     0.19 %
Expected volatility     127 %     125 %
Expected life (in years)     1 to 3 years       1 to 3 years  
Expected dividend yield            
                 
Fair Value:                
Conversion feature   $ 265,403     $ 240,791  

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Deficiency) (Tables)
3 Months Ended
Jun. 30, 2017
Stockholders' Equity Note [Abstract]  
Schedule of Nonvested Restricted Stock Unit Activity

The following table summarizes restricted common stock activity:

 

    Number of Shares  
Non-vested shares, April 1, 2017     1,436,170  
Granted      
Vested      
Forfeited      
Non-vested shares, June 30, 2017     1,436,170  

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Options (Tables)
3 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Stock Option Activity

A summary of the Company’s stock option activity during the three months ended June 30, 2017 is as follows:

 

    Shares     Weighted
Average
Exercise Price
 
Balance outstanding at March 31, 2017     2,820,489     $ 1.27  
Granted              
Exercised              
Expired              
Cancelled              
Balance outstanding at June 30, 2017     2,820,489     $ 1.27  
Balance exercisable at June 30, 2017     1,006,876     $ 1.50  

Schedule of Stock Options Outstanding and Exercisable

A summary of the Company’s stock options outstanding and exercisable as of June 30, 2017 is as follows:

 

    Number of
Options
    Weighted
Average
Exercise Price
    Weighted
Average Grant-
date Stock Price
 
Options Outstanding, June 30, 2017     1,710,821     $ 0.50     $ 0.50  
      153,000     $ 0.96     $ 0.96  
      130,000     $ 1.00     $ 10.00  
      10,000     $ 1.50     $ 1.50  
      647,500     $ 2.00 – 2.79     $ 2.00 – 2.79  
      123,334     $ 3.10 – 3.80     $ 3.10 – 3.80  
      45,834     $ 4.00 – 4.70     $ 4.00 – 4.70  
      2,820,489                  
Options Exercisable, June 30, 2017     427,708     $ 0.50     $ 0.50  
      37,500     $ 0.96     $ 0.96  
      130,000     $ 1.00     $ 10.00  
      7,5000     $ 1.50     $ 1.50  
      235,000     $ 2.00 – 2.79     $ 2.00 – 2.79  
      123,334     $ 3.10 – 3.80     $ 3.10 – 3.80  
      45,834     $ 4.00 – 4.70     $ 4.00 – 4.70  
      1,006,876                  

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Warrants (Tables)
3 Months Ended
Jun. 30, 2017
Warrants and Rights Note Disclosure [Abstract]  
Summary of Warrant Activity

At June 30, 2017, warrants to purchase common shares were outstanding as follows:

 

    Shares     Weighted
Average Exercise Price
 
Balance at March 31, 2017     372,421     $ 2.79  
Granted            
Exercised            
Expired           $  
Balance outstanding and exercisable at June 30, 2017     372,421     $ 2.79  

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2017
Net loss $ 1,106,353 $ 439,405  
Net cash used in operating activities $ 622,164 $ 339,982  
Stock issued during period, shares, new issues 2,650,000    
Warrants to purchase common stock 7,950,000    
Fair value of derivative liabilities $ 265,403   $ 240,791
July 2017 [Member] | Investors [Member]      
Stock issued during period, shares, new issues 666,667    
Warrants to purchase common stock 333,334    
Proceeds from issuance of warrants $ 995,000    
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Antidilutive securities excluded from computation of earnings per share 3,192,910 10,595,213
Options [Member]    
Antidilutive securities excluded from computation of earnings per share 2,820,489 892,500
Warrants [Member]    
Antidilutive securities excluded from computation of earnings per share 372,421 9,702,713
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Derivative Liability (Details Narrative) - USD ($)
3 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Derivative liabilities $ 265,403 $ 240,791
Increase in derivative liabilities $ 24,613  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) - USD ($)
3 Months Ended 12 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Risk-free interest rate   0.19%
Expected volatility 127.00% 125.00%
Expected dividend yield 0.00% 0.00%
Fair Value of Derivative Liability $ 265,403 $ 240,791
Minimum [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Risk-free interest rate 1.14%  
Expected life (in years) 1 year 1 year
Maximum [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Risk-free interest rate 1.55%  
Expected life (in years) 3 years 3 years
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Deficiency) (Details Narrative) - USD ($)
3 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Accumulated vested balance of stock   $ 952,466
Fair value of stock awards that vested $ 102,504  
Stock-based compensation expense not yet recognized $ 307,750  
Stock-based compensation unvested compensation related to awards period 1 year  
Common stock issued for services $ 100,000  
One Consultants [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock issued for services, shares 50,000  
Common stock issued for services $ 10,000  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) - Restricted Stock [Member]
3 Months Ended
Jun. 30, 2017
shares
Non-vested shares, Beginning Balance 1,436,170
Granted
Vested
Forfeited
Non-vested shares, Ending Balance 1,436,170
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Options (Details Narrative) - USD ($)
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]      
Stock-based compensation $ 342,540 $ 39,905  
Unamortized cost of outstanding stock-based awards $ 740,000    
Weighted average remaining vesting period 2 years    
Number of stock options outstanding, shares 2,820,489   2,820,489
Options outstanding, intrinsic value $ 3,050,000    
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Options - Summary of Stock Option Activity (Details)
3 Months Ended
Jun. 30, 2017
$ / shares
shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Shares, beginning balance outstanding | shares 2,820,489
Shares, Granted | shares
Shares, Exercised | shares
Shares, Expired | shares
Shares, Cancelled | shares
Shares, ending balance outstanding | shares 2,820,489
Shares, Balance exercisable | shares 1,006,876
Weighted Average Exercise Price, beginning balance outstanding | $ / shares $ 1.27
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Expired | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price, ending balance outstanding | $ / shares 1.27
Weighted Average Exercise Price, Balance exercisable | $ / shares $ 1.50
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) - $ / shares
3 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 2,820,489 2,820,489
Weighted average grant-date stock price, options outstanding  
Number of options exercisable 1,006,876  
Stock Options One [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 1,710,821  
Weighted average exercise price, options outstanding $ 0.50  
Weighted average grant-date stock price, options outstanding $ 0.50  
Number of options exercisable 427,708  
Weighted average exercise price, options exercisable $ 0.50  
Weighted average grant-date stock price, options exercisable $ 0.50  
Stock Options Two [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 153,000  
Weighted average exercise price, options outstanding $ 0.96  
Weighted average grant-date stock price, options outstanding $ 0.96  
Number of options exercisable 37,500  
Weighted average exercise price, options exercisable $ 0.96  
Weighted average grant-date stock price, options exercisable $ 0.96  
Stock Options Three [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 130,000  
Weighted average exercise price, options outstanding $ 1.00  
Weighted average grant-date stock price, options outstanding $ 10.00  
Number of options exercisable 130,000  
Weighted average exercise price, options exercisable $ 1.00  
Weighted average grant-date stock price, options exercisable $ 10.00  
Stock Options Four [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 10,000  
Weighted average exercise price, options outstanding $ 1.50  
Weighted average grant-date stock price, options outstanding $ 1.50  
Number of options exercisable 75,000  
Weighted average exercise price, options exercisable $ 1.50  
Weighted average grant-date stock price, options exercisable $ 1.50  
Stock Options Five [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 647,500  
Number of options exercisable 235,000  
Stock Options Five [Member] | Minimum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, options outstanding $ 2.00  
Weighted average grant-date stock price, options outstanding 2.00  
Weighted average exercise price, options exercisable 2.00  
Weighted average grant-date stock price, options exercisable 2.00  
Stock Options Five [Member] | Maximum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, options outstanding 2.79  
Weighted average grant-date stock price, options outstanding 2.79  
Weighted average exercise price, options exercisable 2.79  
Weighted average grant-date stock price, options exercisable $ 2.79  
Stock Options Six [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 123,334  
Number of options exercisable 123,334  
Stock Options Six [Member] | Minimum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, options outstanding $ 3.10  
Weighted average grant-date stock price, options outstanding 3.10  
Weighted average exercise price, options exercisable 3.10  
Weighted average grant-date stock price, options exercisable 3.10  
Stock Options Six [Member] | Maximum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, options outstanding 3.80  
Weighted average grant-date stock price, options outstanding 3.80  
Weighted average exercise price, options exercisable 3.80  
Weighted average grant-date stock price, options exercisable $ 3.80  
Stock Options Seven [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of options outstanding 45,834  
Number of options exercisable 45,834  
Stock Options Seven [Member] | Minimum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, options outstanding $ 4.00  
Weighted average grant-date stock price, options outstanding 4.00  
Weighted average exercise price, options exercisable 4.00  
Weighted average grant-date stock price, options exercisable 4.00  
Stock Options Seven [Member] | Maximum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise price, options outstanding 4.70  
Weighted average grant-date stock price, options outstanding 4.70  
Weighted average exercise price, options exercisable 4.70  
Weighted average grant-date stock price, options exercisable $ 4.70  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Warrants - Summary of Warrant Activity (Details)
3 Months Ended
Jun. 30, 2017
$ / shares
shares
Warrants and Rights Note Disclosure [Abstract]  
Shares, Outstanding Beginning Balance | shares 372,421
Shares, Granted | shares
Shares, Exercised | shares
Shares, Expired | shares
Shares, outstanding and exercisable Balance | shares 372,421
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 2.79
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Expired/Cancelled | $ / shares
Weighted Average Exercise Price, Outstanding and Ending Balance | $ / shares $ 2.79
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions and Lease Obligations (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
May 01, 2017
Apr. 23, 2012
Jun. 30, 2017
Jun. 30, 2016
Operating Leased Assets [Line Items]        
Operating leases, net rent expense     $ 7,500 $ 6,900
Lease Agreement [Member] | One World Ranches [Member]        
Operating Leased Assets [Line Items]        
Lease description   The original term of the lease was from May 1, 2012 to May 1, 2017. In May 2017, the Company extended the lease through May 1, 2020.    
Payments for rent per month   $ 2,300    
Lease expiration date May 01, 2017      
Increase payment for rent per month $ 2,600      
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments (Details Narrative)
3 Months Ended
Jun. 30, 2017
USD ($)
shares
Commitments and Contingencies Disclosure [Abstract]  
Accrued legal fees | $ $ 44,000
Stock issued during period, shares, new issues 2,650,000
Common stock issuable upon exercise of warrants 7,950,000
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Events (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jul. 26, 2017
Jul. 31, 2017
Jun. 30, 2017
Mar. 31, 2017
Stock issued during period, shares, new issues     2,650,000  
Warrants to purchase common stock     7,950,000  
Exercise price of warrants     $ 2.79 $ 2.79
Number of option issued to purchase common stock      
Exercise price, option granted      
Stock option, award vesting period     1 year  
Subsequent Event [Member]        
Number of option issued to purchase common stock   30,000    
Fair value of stock option grants   $ 50,127    
Exercise price, option granted   $ 1.79    
Stock option, volatility rate   126.91%    
Stock option, discount rate   2.20%    
Stock option, expected dividend yield   0.00%    
Stock option, expected term   5 years    
Stock option, award vesting period   24 months    
Subsequent Event [Member] | Securities Purchase Agreement [Member]        
Stock issued during period, shares, new issues 666,667      
Warrants to purchase common stock 333,334      
Stock issued price per share $ 1.50      
Exercise price of warrants $ 2.00      
Aggregate proceeds from sale of the shares and warrants $ 995,000      
EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 59 143 1 false 22 0 false 4 false false R1.htm 00000001 - Document - Document And Entity Information Sheet http://vitality.bio/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://vitality.bio/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://vitality.bio/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://vitality.bio/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) Sheet http://vitality.bio/role/StatementOfChangesInStockholdersEquityDeficiency Condensed Statement of Changes in Stockholders' Equity (Deficiency) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://vitality.bio/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Business Operations and Summary of Significant Accounting Policies Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies Business Operations and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Derivative Liability Sheet http://vitality.bio/role/DerivativeLiability Derivative Liability Notes 8 false false R9.htm 00000009 - Disclosure - Stockholders' Equity (Deficiency) Sheet http://vitality.bio/role/StockholdersEquityDeficiency Stockholders' Equity (Deficiency) Notes 9 false false R10.htm 00000010 - Disclosure - Stock Options Sheet http://vitality.bio/role/StockOptions Stock Options Notes 10 false false R11.htm 00000011 - Disclosure - Warrants Sheet http://vitality.bio/role/Warrants Warrants Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Obligations Sheet http://vitality.bio/role/RelatedPartyObligations Related Party Obligations Notes 12 false false R13.htm 00000013 - Disclosure - Commitments Sheet http://vitality.bio/role/Commitments Commitments Notes 13 false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://vitality.bio/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Policies) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesPolicies Business Operations and Summary of Significant Accounting Policies (Policies) Policies http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Tables) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesTables Business Operations and Summary of Significant Accounting Policies (Tables) Tables http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Derivative Liability (Tables) Sheet http://vitality.bio/role/DerivativeLiabilityTables Derivative Liability (Tables) Tables http://vitality.bio/role/DerivativeLiability 17 false false R18.htm 00000018 - Disclosure - Stockholders' Equity (Deficiency) (Tables) Sheet http://vitality.bio/role/StockholdersEquityDeficiencyTables Stockholders' Equity (Deficiency) (Tables) Tables http://vitality.bio/role/StockholdersEquityDeficiency 18 false false R19.htm 00000019 - Disclosure - Stock Options (Tables) Sheet http://vitality.bio/role/StockOptionsTables Stock Options (Tables) Tables http://vitality.bio/role/StockOptions 19 false false R20.htm 00000020 - Disclosure - Warrants (Tables) Sheet http://vitality.bio/role/WarrantsTables Warrants (Tables) Tables http://vitality.bio/role/Warrants 20 false false R21.htm 00000021 - Disclosure - Business Operations and Summary of Significant Accounting Policies (Details Narrative) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Business Operations and Summary of Significant Accounting Policies (Details Narrative) Details http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://vitality.bio/role/BusinessOperationsAndSummaryOfSignificantAccountingPolicies-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Business Operations and Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 22 false false R23.htm 00000023 - Disclosure - Derivative Liability (Details Narrative) Sheet http://vitality.bio/role/DerivativeLiabilityDetailsNarrative Derivative Liability (Details Narrative) Details http://vitality.bio/role/DerivativeLiabilityTables 23 false false R24.htm 00000024 - Disclosure - Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) Sheet http://vitality.bio/role/DerivativeLiability-ScheduleOfValuationAssumptionsForDerivativeLiabilitiesDetails Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details) Details 24 false false R25.htm 00000025 - Disclosure - Stockholders' Equity (Deficiency) (Details Narrative) Sheet http://vitality.bio/role/StockholdersEquityDeficiencyDetailsNarrative Stockholders' Equity (Deficiency) (Details Narrative) Details http://vitality.bio/role/StockholdersEquityDeficiencyTables 25 false false R26.htm 00000026 - Disclosure - Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) Sheet http://vitality.bio/role/StockholdersEquityDeficiency-ScheduleOfNonvestedRestrictedStockUnitActivityDetails Stockholders' Equity (Deficiency) - Schedule of Nonvested Restricted Stock Unit Activity (Details) Details http://vitality.bio/role/StockholdersEquityDeficiencyTables 26 false false R27.htm 00000027 - Disclosure - Stock Options (Details Narrative) Sheet http://vitality.bio/role/StockOptionsDetailsNarrative Stock Options (Details Narrative) Details http://vitality.bio/role/StockOptionsTables 27 false false R28.htm 00000028 - Disclosure - Stock Options - Summary of Stock Option Activity (Details) Sheet http://vitality.bio/role/StockOptions-SummaryOfStockOptionActivityDetails Stock Options - Summary of Stock Option Activity (Details) Details 28 false false R29.htm 00000029 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Sheet http://vitality.bio/role/StockOptions-ScheduleOfStockOptionsOutstandingAndExercisableDetails Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Details 29 false false R30.htm 00000030 - Disclosure - Warrants - Summary of Warrant Activity (Details) Sheet http://vitality.bio/role/Warrants-SummaryOfWarrantActivityDetails Warrants - Summary of Warrant Activity (Details) Details 30 false false R31.htm 00000031 - Disclosure - Related Party Transactions and Lease Obligations (Details Narrative) Sheet http://vitality.bio/role/RelatedPartyTransactionsAndLeaseObligationsDetailsNarrative Related Party Transactions and Lease Obligations (Details Narrative) Details 31 false false R32.htm 00000032 - Disclosure - Commitments (Details Narrative) Sheet http://vitality.bio/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://vitality.bio/role/Commitments 32 false false R33.htm 00000033 - Disclosure - Subsequent Events (Details Narrative) Sheet http://vitality.bio/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://vitality.bio/role/SubsequentEvents 33 false false All Reports Book All Reports vbio-20170630.xml vbio-20170630.xsd vbio-20170630_cal.xml vbio-20170630_def.xml vbio-20170630_lab.xml vbio-20170630_pre.xml true true ZIP 50 0001493152-17-008899-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-008899-xbrl.zip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end